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Abstract 
In acute graft-versus-host disease (GVHD) alloreactive donor T cells selectively damage 
skin, liver, and the gastrointestinal tract while other organs are rarely affected. The 
mechanism of this selective target tissue infiltration is not well understood. We investigated 
the importance of alloantigen expression for the selective organ manifestation by examining 
spatiotemporal changes of cellular and molecular events after allogeneic hematopoietic cell 
transplantation (allo-HCT). 
To accomplish this we established a novel multicolor light sheet fluorescence microscopy 
(LSFM) approach for deciphering immune processes in large tissue specimens on a single-
cell level in 3 dimensions. We combined and optimized protocols for antibody penetration, 
tissue clearing, and triple-color illumination to create a method for analyzing intact mouse 
and human tissues. This approach allowed us to successfully quantify changes in expression 
patterns of mucosal vascular addressin cell adhesion molecule–1 (MAdCAM-1) and T cell 
responses in Peyer’s patches following allo-HCT. In addition, we proofed that LSFM is 
suitable to map individual T cell subsets after HCT and detected rare cellular events. We 
employed this versatile technique to study the role of alloantigen expression for the selective 
organ manifestation after allo-HCT. Therefore, we used a T cell receptor (TCR) transgenic 
mouse model of GVHD that targets a single peptide antigen and thereby mimics a major 
histocompatibility complex (MHC)-matched single antigen mismatched (miHAg-mismatched) 
HCT. We transplanted TCR transgenic (OT-I) T cells into myeloablatively conditioned hosts 
that either express the peptide antigen ovalbumin ubiquitously (βa-Ova) or selectively in the 
pancreas (RIP-mOva), an organ that is normally not affected by acute GVHD. Of note, at 
day+6 after HCT we observed that OT-I T cell infiltration occurred in an alloantigen 
dependent manner. In βa-Ova recipients, where antigen was ubiquitously expressed, OT-I T 
cells infiltrated all organs and were not restricted to gastrointestinal tract, liver, and skin. In 
RIP-mOva recipients, where cognate antigen was only expressed in the pancreas, OT-I T 
cells selectively infiltrated this organ that is usually spared in acute GVHD. In conditioned 
RIP-mOva the transfer of 100 OT-I T cells sufficed to effectively infiltrate and destroy 
pancreatic islets resulting in 100% mortality. By employing intact tissue LSFM in RIP-mOva 
recipients, we identified very low numbers of initial islet infiltrating T cells on day+4 after HCT 
followed by a massive T cell migration to the pancreas within the following 24 hours. This 
suggested an effective mechanism of effector T cell recruitment to the tissue of alloantigen 
expression after initial antigen specific T cell encounter. In chimeras that either expressed the 
model antigen ovalbumin selectively in hematopoietic or in parenchymal cells only, 
transplanted  
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OT-I T cells infiltrated target tissues irrespective of which compartment expressed the 
alloantigen. As IFN-γ could be detected in the serum of transplanted ovalbumin expressing 
recipients (βa-Ova, βa-Ova-chimeras and RIP-mOva) at day+6 after HCT, we hypothesized 
that this cytokine may be functionally involved in antigen specific OT-I T cell mediated 
pathology. In vitro activated OT-I T cells responded with the production of IFN-γ upon antigen 
re-encounter suggesting that IFN-γ might be relevant in the alloantigen dependent organ 
infiltration of antigen specific CD8+ T cell infiltration after HCT. Based on these data we 
propose that alloantigen expression plays an important role in organ specific T cell infiltration 
during acute GVHD and that initial alloreactive T cells recognizing the cognate antigen 
propagate a vicious cycle of enhanced T cell recruitment that subsequently culminates in the 
exacerbation of tissue restricted GVHD. 
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Zusammenfassung 
In der akuten Graft-Versus-Host Disease (GVHD) infiltrieren allogene Spender T Zellen Haut, 
Leber und den Magen-Darm-Trakt des Empfängers und attackieren das Gewebe. Andere 
Organe sind dagegen interessanterweise nur selten betroffen. Die Mechanismen dieser 
selektiven Organinfliltration sind bisher weitestgehend unbekannt. In meiner 
Dissertationsarbeit untersuchte ich den Einfluss der Alloantigenexpression auf die selektive 
Organmanifestation während der GVHD.  
Um komplexe Immunprozesse die nach allogener Stammzelltransplantation auftreten, 
besser zu verstehen, entwickelten wir eine Lichtblattmikroskopietechnik (LSFM) die zelluläre 
und molekulare Veränderungen im intakten Gewebe detektieren kann. Wir etablierten eine 
neuartigen mehrfarben LSFM-Methodik, die es ermöglicht, Immunprozesse in großen 
Gewebsstücken von Maus und Mensch in Einzelzellauflösung dreidimensional darzustellen. 
Dazu kombinierten und optimierten wir Protokolle, um eine Penetration von Antikörpern tief in 
das Gewebe sowie die Aufklärung und die dreifache Beleuchtung des Gewebes zu 
ermöglichen. Diese Methode erlaubte uns die erfolgreiche Quantifizierung der 
Proteinexpression des Adressins mucosal vascular addressin cell adhesion molecule–1 
(MAdCAM-1) als auch die Quantifizierung der T Zell Antwort im intakten Peyer’s Plaque nach 
allogener hämatopoetischer Transplantation (HCT). Weiterhin konnten wir die Methode zur 
Untersuchung der Migration unterschiedlicher T Zell-Subpopulationen nach HCT erfolgreich 
einsetzen und konnten einzelne, organinfiltrierende Zellen detektierten und quantifizieren. 
Wir benutzten die LSFM Methode um den Einfluss der Alloantigenexpression auf die 
selektive Organmanifestation zu studieren. Dazu verwendeten wir ein 
Transplantationsmodell, in dem der Haupthistokompatibilitätskomplex übereinstimmt (MHC-
matched) und eine Diskrepanz nur in einem einzelnen Peptid Antigen (miHAG-mismatch) 
zwischen Spender und Empfänger bestand. Wir transplantierten T Zell Rezeptor (TCR) 
transgene (OT-I) T Zellen in myeloablativ bestrahlte Empfänger, die das Peptidantigen 
Ovalbumin entweder in allen Geweben (βa-Ova) oder selektiv in der Bauchspeicheldrüse 
(RIP-mOva) exprimieren. Die Bauchspeicheldrüse ist ein Organ, das normalerweise nicht 
von der akuten GVHD betroffen ist. An Tag 6 nach allogener HCT waren alle Organe die das 
Alloantigen exprimieren auch von Spender T Zellen infiltriert. In myeloablativ bestrahlten RIP-
mOva Empfängern reichten bereits 100 transferierte OT-I T Zellen aus, um Alloantigen-
exprimierende pankreatische Inselzellen zu zerstören. Dies führte zu einer Mortalität von 
100% der Empfänger und spricht für eine sehr effiziente Alloantigendetektion und 
Gewebsinfiltration durch die Spender T Zellen. Um die Kinetik der Organinfiltration der 
Spender T Zellen detailliert zu untersuchen, verwendeten wir die neue 
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Lichtblattmikroskopietechnik, welche die Analyse intakter Organe ermöglicht. In RIP-mOva 
Empfängern identifizierten wir erste wenige Spender T Zellen im Pankreas an Tag 4 nach 
Transplantation, gefolgt von einer massiven Pankreasinfiltration durch Spender T Zellen 
innerhalb von 24 Stunden. Dies deutet auf eine gezielte Rekrutierung der Spender T Zellen 
nach erstem Antigenkontakt in das Gewebe mit Alloantigenexpression. Um zu untersuchen, 
ob die Alloantigenexpression vom parenchymalen Gewebe oder aber durch 
hämatopoetische Zellen zur spezifischen Organinfiltration führt, transplantierten wir OT-I T 
Zellen in chimäre Empfänger, in denen das Alloantigen entweder nur im Gewebsparenchym 
oder ausschließlich von hämatopoetischen Zellen exprimiert wird. An Tag 6 nach der 
allogenen HCT fanden wir Spender T Zellen in allen Geweben, unabhängig davon welches 
Empfängerzellkompartment das Alloantigen präsentierte. Wir detektierten hohe IFN-γ-Werte 
im Serum von Ovalbumin exprimierenden Empfänger (βa-Ova, βa- Ova-Chimären und RIP-
mOva). Weiterhin fanden wir, dass nach erneutem Kontakt mit dem spezifischen Alloantigen, 
OT-I T Zellen die in vitro aktiviert wurden, IFN-γ produzierten. Wir schließen aus diesen 
Beobachtungen, dass für die antigenabhängige Gewebeinfiltration IFN-γ wichtig ist. 
Zusammenfassend postulieren wir, dass die Alloantigenexpression im Gewebe eine wichtige 
Rolle in der organspezifischen Infiltration durch Spender T Zellen spielt, und dass T Zellen 
die Alloantigen spezifisch erkennen, dafür verantwortlich sind, dass weitere Effektor-T Zellen 
in das Gewebe rekrutiert werden.  
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1 Introduction 
1.1 Selective organ manifestation in Graft-versus-Host Disease 
1.1.1 Hematopoietic cell transplantation and complications in the clinic  
Hematopoietic cell transplantation (HCT) is a potentially curative therapy that is used for 
numerous hematological and lymphoid cancers as well as for inherited disorders of blood 
cells. Based on the source of the donated stem cells, the graft is categorized as autologous 
(from the same patient) or as allogeneic (from a foreign donor). In an allogeneic HCT (allo-
HCT), donor T cells are critical for reconstituting T cell immunity in the host and mediate an 
antitumor effect called graft-versus-leukemia (GVL). The source of graft that is used normally 
depends on the availability and on the indication. The degree of human leukocyte antigen 
(HLA, human) match between the donor and the recipient is an important factor to assess 
the risk of acute Graft-versus-Host Disease (GVHD). GVHD is a life-threatening complication 
that generally occurs after allo-HCT and is a reaction of donor immune cells against host 
tissues. The syndrome is mediated by donor T cells that recognize the recipient as 'non-self' 
and attack host tissues by employing a wide range of immune mechanisms. Mainly three 
tissues are affected by acute GVHD: skin, liver, and the gastrointestinal tract. Bone marrow 
transplantation usually requires a preparatory conditioning regimen of the recipient, either by 
immunosuppressive medications, irradiation or a combination of both, to suppress immune 
reactions and prevent the rejection of the graft. The immunosuppressed patient is highly 
susceptible to viral, fungal and bacterial infections up to several months after HCT until the 
complete engraftment of the transplanted cells. Hence, besides acute GVHD as the major 
complication following HCT (Ferrara and Reddy, 2006) infections and leukemia relapse are 
further sources of morbidity and mortality following HCT, limiting the treatment of a broader 
spectrum of diseases. 
About 60,000 patients are treated with hematopoietic stem cells per year worldwide 
(Gyurkocza et al., 2010) and the number of treatments are increasing. The incidence of acute 
GVHD in patients who receive allogeneic donor cells without previous depletion of T cells 
range from 10% to 80%, dependent on the risk factors and prophylaxis (Sullivan, 2004). The 
risk of acute GVHD can be significantly reduced by T cell depletion of the graft, but this 
generally results in an increased relapse risk, higher infectious morbidity and a reduced GVL 
effect. Because of this, it is attempted to balance the risk by giving sufficient immune 
INTRODUCTION 
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suppression to prevent most severe acute GVHD whilst preserving the positive effects of 
GVL and immune reconstitution. 
1.1.2 Target antigen recognition 
The pathogenesis of acute GVHD is currently understood to occur in three sequential phases 
(Ferrara et al., 1999): In the first phase, the antigen-presenting cells (APCs) are activated 
due to the conditioning regimen that also leads to damage of host tissues. In the second 
phase activation and proliferation of donor T cells takes place. Upon interaction with host 
APCs donor T cells that have recognized an alloantigen become activated, and differentiate 
into effector cells. The third phase is the effector phase of GVHD. Activated effector T cells 
are recruited to peripheral tissues such as the skin and gut (Beilhack et al., 2005) where they 
cause profound tissue damage that characterizes GVHD. The cause of the selective GVHD 
organ manifestation still remains elusive. However, understanding the tissue-specific 
infiltration of GVHD target organs appears of fundamental importance as the anatomical 
separation of GVHD and the desired anti tumor effect poses an attractive mechanism to 
discern GVHD from graft-versus-tumor responses that could be exploited therapeutically. 
Secondary lymphoid organs (SLOs), such as spleen, lymph nodes or Peyer’s patches 
(Figure 1.1), enable interactions between activated APCs and antigen-specific T cells that, 
upon contact, get activated proliferate and differentiate into effector T cells that migrate to the 
selective target tissues. Hence, SLOs were demonstrated to be essential for the priming of 
alloreactive T cells, but the lack of certain priming sites resulted neither in reduced, nor in 
delayed acute GVHD (Beilhack et al., 2008). For example previous studies have been 
demonstrated the importance of Peyer’s patches in the induction of GVHD because 
recipients lacking these lymphoid organs did not develop acute GVHD under certain 
experimental conditions (Murai et al., 2003). However, by using a myeloablative conditioning 
mouse model, T-cell activation and proliferation was shown to occur in several SLOs 
including Peyer’s patches and that animals that lacked Peyer’s patches still developed acute 
GVHD (Welniak et al., 2006; Beilhack et al., 2008). 
Another fundamental aspect in GVHD is the identity of the target antigen that is recognized 
by the T cells after HCT. In MHC-matched transplantations, T cells can recognize minor 
histocompatibility antigens (miHAgs), which are the distinct peptide products of polymorphic 
genes that are present in the recipient but not in the donor (Figure 1.2A). For the recognition 
of MHC-bound miHAgs the T cell receptor (TCR) has to be in contact with both the peptide 
INTRODUCTION 
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Figure 1.1: Peyer’s patches (PPs) are important sites of adaptive immune responses. PPs are 
aggregations of lymphoid tissue located in the small bowel. (A) Scheme illustrates important 
structures and organization of a PP. The follicular areas mainly consist of B-lymphocytes, follicular 
dendritic cells and macrophages and the interfollicular structures are populated by T cells, 
macrophages and dendritic cells. PPs are connected to the body via lymphatic vessels and 
endothelial venules. Naïve lymphocytes immigrate into the PP via specialized high endothelial 
venules that express MAdCAM-1. (B) Immunufluorescence microscopy of a PP from an untreated wt 
mouse. Nuclei, stained with DAPI, MAdCAM-1 (green) B cells (red). PPs are the interface between 
bacterial environment and immune response having a pivotal role in alloresponse and inflammation.  
and the MHC molecule. In MHC-mismatched transplantations the TCR primarily recognizes 
intact epitopes on MHC molecules as foreign (Figure 1.2B). The precursor frequency of T 
cells that can recognize a mismatched MHC molecule in an allo-HCT is very high 
(Shlomchik, 2007). 
Figure 1.2: Antigen recognition by 
donor T-cells after allo-HCT. A) In MHC-
matched minor histocompatibility antigens 
(miHAgs) mismatched transplants, T-cell 
receptors (TCRs) of donor T cells can 
recognize foreign peptides presented by 
allogeneic MHC molecules. This TCR-
peptide recognition resembles the 
recognition of pathogen-derived antigens. 
B) In MHC-mismatched transplants, the 
TCR of the donor T cell bind the allogeneic 
MHC molecule, independent of the loaded 
peptide. Sketch taken from (Shlomchik, 
2007). 
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1.1.3 CD4 versus CD8 T cell mediated immune responses 
The T cell co-receptors CD4 and CD8 bind the constant regions of the major 
histocompatibility complex (MHC) class II and class I molecules, respectively (Csencsits and 
Bishop, 2003). Foreign peptides presented by MHC class I stimulate CD8+ T cells, while 
CD4+ T cells recognize peptides presented by MHC class II. CD4+ T helper cells are well 
known for their importance in providing critical signals during priming of cytotoxic T cell (CTL) 
responses in vivo. T cell help is required for the generation of primary CTL responses as well 
as in promoting memory CD8+ T cell development (Williams and Bevan, 2007). Generally 
CD4+ T cells provide help for CD8+ CTL expansion and development via IL-2 production or 
enhancing the stimulatory capacity of APC to CD8+ CTLs by CD40L-CD40 interactions. The 
route of antigen delivery (Bour et al., 1998), the avidity of the TCR-antigen binding (Heath et 
al., 1993) and the frequency of the CD8+ effector cells (Wang et al., 2001) may influence an 
CD4 helper independent development of CD8 responses. 
In a model of viral infections, the generation of primary CD8+ T cell responses to herpes 
simplex virus (HSV) required help from CD4+ T cell (Jennings et al., 1991), whereas primary 
CTL responses to acute infection with Listeria monocytogenes and lymphocytic 
choriomeningitis virus can occur in the absence of CD4+ T cells. Recently, it was shown that 
CD4+ T cell help was not only necessary for effector CTL stimulation, but also provided the 
necessary cue for an effective CD8+ T cell migration to HSV infected tissue (Nakanishi et al., 
2009). 
In models of immune-mediated disease, CD4-independent CD8+ T cell responses have been 
reported to be common, like in autoimmune diabetes (Graser et al., 2000), tumor rejection 
(Yamazaki et al., 1999) or xenograft rejection (YI et al., 2000). In GVHD, the roles of 
individual CD4+ and CD8+ T cells have been intensively studied by employing various mouse 
models (Reviewed in Reddy and Ferrara, 2009; Schroeder and DiPersio, 2011). In MHC 
mismatched HCT both, CD4+ or CD8+ T cells are capable to induce GVHD. Allogeneic CD4+ 
T cells precede the increase of donor CD8+ T cells in lymphoid organs during GVHD initiation 
and also appeared earlier in the small intestines after HCT followed by infiltrating cytotoxic T 
cells (Beilhack et al., 2005). Also in miHAg-mismatched mouse models, either CD8+ T cells, 
CD4+ T cells, or both can contribute to GVHD dependent on the strain combination of donor 
and recipient (examples listed in: Reddy and Ferrara, 2009; Schroeder and DiPersio, 2011). 
CD8+ T cells induce GVHD primarily by cytolytic activity, which requires the engagement of 
the T cell receptor (TCR) with the MHC on target tissue (Reddy et al., 2009). Proliferating 
CD4+ T cells may differentiate into type 1, type 2 or type 17 helper cells (Th1, Th2 or Th17). 
Th1 cells produce cytokines, such as IFN-γ, TNF-α and IL-2 that have been implicated in the 
pathophysiology of acute GVHD (Ferrara and Krenger, 1998; Reddy and Ferrara, 2003). Th2 
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cells can migrate to the lung, where they secrete IL-4 and IL-13 causing inflammation on lung 
epithelium (Coghill et al., 2011). Th17 T cells have been demonstrated to contribute to acute 
GVHD by augmenting Th1 cell differentiation (Yi et al., 2008; Zhao et al., 2011). 
Finally, different CD4+ and CD8+ T cell subsets, such as naive, effector memory, central 
memory and regulatory T (Treg) cells either separately or together have been shown to 
influence the outcome after HCT dramatically (reviewed in Leventhal et al., 2012).  
1.1.4 Direct and cross-presentation of alloantigens in GVHD 
In GVHD, antigen presenting cells (APCs) take up antigen in peripheral tissues, migrate to 
the draining lymph nodes (LNs), and present the tissue-derived MHC-peptide complexes to T 
lymphocytes. Dendritic cells (DCs) can take up antigen using different mechanisms and are 
very well equipped to form class II and class I peptide-MHC complexes. The presentation of 
peptide-MHC class II complexes to CD4+ T cells is called direct presentation and can be 
mediated by all APCs, including DCs, macrophages, and B cells (Banchereau et al., 2000). 
In contrast, CD8+ T cells recognize peptides associated with MHC class I molecules, which 
are expressed on the surface of all cells. The peptides presented on MHC class I molecules 
of most cells are normally derived from endogenous proteins. Exclusively DCs have the 
ability to load peptides derived from exogenous antigens onto MHC class I molecules 
(Guermonprez et al., 2003). This mechanism is called cross-presentation and can lead to the 
initiation of an immunogenic CD8+ cell response. Cross-priming is an important mechanism 
to activate cytotoxic T lymphocytes (CTLs) for immune defense against viruses that do not 
infect APCs and tumors. Furthermore cross-priming is involved in immune-mediated 
diseases such as type 1 diabetes. CTLs are the main effector cells of type 1 diabetes in 
humans. In transgenic mouse models of diabetes cross-priming is necessary and sufficient 
for an efficient islet infiltration and destruction (Carbone et al., 1998). 
The role of cross-presentation and –priming after allo-HCT has been investigated in miHAg 
mismatched CD8+ T cell-dependent models of GVHD, with different outcomes. The study of 
Shlomshik et al. (1999) demonstrated the requirement of host APCs expressing MHC class I 
to initiate GVHD, suggesting cross-priming via donor APCs is not sufficient for GVHD 
induction. In contrast, it could be shown that cross-priming of MHC-I-presented miHAgs can 
significantly contribute to GVHD (Wang et al., 2011). In this study non-hematopoietic and 
hematopoietic antigens were cross-presented and targeted by alloreactive CD8+ T cells. 
Exclusively donor CD11c+ DCs were found to cross-prime CD8+ T cells. However, in most 
mouse models progenitors of donor APCs are transferred with the graft and have to develop 
from hematopoietic stem cells, too late to contribute to the initiation of GVHD. Nevertheless, 
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when host APCs are largely replaced by donor-derived cells they may drive further tissue 
injury by cross-presentation of host antigens. Thus, in experiments in which donor APCs are 
selectively prevented from cross-presenting host antigens, GVHD still occurs, but its 
incidence and severity are sharply diminished (Matte et al., 2004). Importantly, in a model of 
single minor MHC mismatched T cells it could be shown that the antigen can be efficiently 
cross-presented by either host or donor APCs to initiate GVHD (Toubai et al., 2012). 
1.1.5 T cell trafficking in GVHD 
Understanding the T cell trafficking after HCT to specific sites is an important aspect in 
GVHD, and has become the focus of a growing body of research. Generally, donor T cells 
are infused intravenously into the recipient and have to migrate to and within secondary 
lymphoid tissues, where they recognize alloantigens on either host or donor APCs and 
become activated. After 3 to 4 days, large numbers of T cells exit the lymphoid tissues and 
migrate to the target organs causing tissue damage (Beilhack et al., 2005; Wysocki et al., 
2005).  
Transplanted T cells are homing to lymphoid tissues within hours after administration 
(Panoskaltsis-Mortari et al., 2004; Beilhack et al., 2005). It is well established, that 
chemokines and the expression of selectins and integrins and their ligands play an important 
role in T cell trafficking to secondary lymphoid organs, as well as to the target tissues (Cyster, 
2005). For example, the expression of CD62L by T cells is critical for their homing into 
secondary lymphoid tissues (Beilhack et al., 2008). The interaction between α4β7 integrin 
and its ligand MAdCAM-1, which is expressed by high endothelial venules (HEV), was shown 
to be important for homing of donor T cells to Peyer's patches (Murai et al., 2003). 
Furthermore T cell homing to lymphoid tissues might depend on other factors induced by the 
conditioning regimen or the inflammatory milieu (Murai et al., 2003; Welniak et al., 2006). 
Chemokines that are constitutively expressed and control cell movement during homeostasis 
are CCL19 and CCL21 that bind to the receptor CCR7, which is expressed by various 
subsets of immune cells (Gunn et al., 1998; Rot and von Andrian, 2004). CCR7 and its 
ligands, functioning on HEVs, are essentially involved in the homing of T cells into lymph 
nodes. T cell access to and the priming within secondary lymphoid organs is essential for 
initialization of GVHD and blocking completely the T cell entry to secondary lymphoid organs 
prevented acute GHVD (Beilhack et al., 2008). 
Although the migration of T cells into lymphoid tissues is well characterized, the migration 
into the selective target organs during GVHD is less well understood. One possible 
explanation for the selective organ manifestation in acute GVHD is that alloreactive effector T 
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cells are instructed within the lymphoid organs to migrate to corresponding target tissues. For 
example, T cells encountering antigen in a skin draining LN would be imprinted to migrate to 
the skin (Campbell and Butcher, 2002). Several studies support this concept, suggesting that 
homing properties of T cells are imprinted during the initiation of an immune response 
(Campbell and Butcher, 2002; Mora et al., 2003; Stenstad et al., 2006) and once activated, 
effector T cells can target organs independently of antigen recognition (Teshima et al., 2002). 
In accordance with prior studies, Beilhack et al. (2008) found that, although homing receptor 
acquisition in SLOs is nonstochastic, alloreactive T cells infiltrated GVHD target tissues 
irrespective of their initial priming site. In this regard, local imprinting of alloreactive T cell 
trafficking in GVHD initiation sites appears to play a minor role. Instead, GVHD target tissues 
appear to selectively attract alloreactive T cells (Davenport et al., 2000). Unlike specific 
pathogen–induced tissue inflammation, that supports T cell migration into affected tissues via 
vascular endothelial changes and chemokine gradients, in GVHD all tissues are initially 
damaged from total body irradiation or chemotherapy. Anyway, the severity of damage 
caused by conditioning might depend on the tissues susceptibility, causing a selective tissue 
manifestation. Inflammation induced by host conditioning plays an important role in the initial 
recruitment of T cells, which induce an inflammatory cascade promoting further recruitment 
of T cells to GVHD target organs (Chakraverty et al., 2006). However, GVHD can also occur 
without irradiation (Murai et al., 2003), and therefore other mechanisms must be sufficient for 
target organ infiltration. Allogeneic transplantations in germ free mice have a greatly reduced 
incidence of acute GVHD (Van Bekkum and Knaan, 1977) and led to the hypothesis of the 
involvement of microbial vicinity to explain the selective organ manifestation. In fact, all target 
organs have in common to be barriers to microorganisms and might have a greater 
propensity to recruit activated T cells. Especially skin and gut are regularly exposed to 
microorganisms and also the liver functions as a barrier to endotoxin and gram-negative 
bacteria that pass through the intestinal mucosa (Ferrara et al., 1999). Also the bronchial 
epithelium of the lung, as being discussed to be a GVHD target organ, is likewise an 
important barrier to infection. Thus bacterial products like lipopolysaccharides (LPS) might be 
released into circulation and peripheral tissues by the conditioning regimen, with activating 
macrophages and subsequently releasing high levels of pro-inflammatory cytokines (Cooke 
et al., 2001). Indeed, many experimental studies have shown that the conditioning of the host 
activate the production of cytokines, such as IFN-γ, TNF-α IL-1, IL-2, that are important in the 
pathogenesis of acute GVHD (e.g. Hill et al., 1997; Mapara et al., 2006; Kittan and 
Hildebrandt, 2010). For example, IL-2 promotes T cell activation and expansion (Jaksch and 
Mattsson, 2005). During the initial phase of GVHD, especially IFN-γ and TNF-α are 
considered to induce the production of chemokines in target organs (Schroeder and 
DiPersio, 2011). 
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Further molecular mechanisms that have been shown to be involved in directing T cell 
migration to GVHD target tissues are interactions between chemokines and chemokine 
receptors, integrins and selectins with adhesion molecules (reviewed in Wysocki et al., 
2005). Chemokines play an important role in recruiting cells of the innate and adaptive 
immune system to sites of inflammation (Rollins, 1997; Moser et al., 2004) and the 
expression of chemokines can be enhanced by inflammatory cytokines (Mackay, 2001). The 
expression profile of chemokine and chemokine receptor during GVHD greatly differs 
between the target organs of GVHD. Several chemokines such as CCL2–5, CXCL2, 
CXCL9–11, CCL17 and CCL27 were found to play a role in target infiltration during acute 
GVHD (Cyster, 2005; Mapara et al., 2006). The production of CCL3 during acute GVHD is 
critical for the recruitment of CD8+ but not CD4+ T cells to the liver, lung, and spleen (Serody 
et al., 2000). In studies of conditioned mouse models CXCR3+ T cells and CCR5+ T cells 
caused acute GVHD in the liver, gastrointestinal tract, and lung (Murai et al., 1999; 
Hildebrandt et al., 2004; Wysocki et al., 2004). In vivo administration of CCR5 or CXCR3 
neutralizing antibody reduced the infiltration of alloreactive CD8+ T cells into GVHD target 
organs (Murai et al., 1999; He et al., 2008). The selectin ICAM-1 and its interaction to α4β1 
have been shown to be important for T cell homing to the lung (Panoskaltsis-Mortari et al., 
2001) and the liver (Harning et al., 1991). For example, the homing of alloreactive T cells to 
the gastrointestinal tract during GVHD, especially the interaction between MAdCAM-1 and 
α4β7 integrin, is important (Petrovic et al., 2004). 
1.1.6 Importance of alloantigen expression in GVHD 
Already 40 years ago, Billingham proposed the requirement of alloantigen expression within 
the recipient tissue to be crucial for the development of GVHD (Billingham, 1966). More 
recently, it became clear that alloantigen expression is essential for the activation phase of 
acute GVHD (Shlomchik et al., 1999). For a long time it was believed that also the effector 
phase of GVHD is antigen-specific and requires alloantigen expression on the host target 
epithelium (Lampert et al., 1981). However, in the last decade several studies either 
confirmed or challenged this assumption raising some unresolved controversies in the field.  
Teshima et al. (2002) suggested that the damage to GVHD target organs does not require 
alloantigen expression on epithelial target cells and alloantigen expression by hematopoietic 
cells alone was sufficient for both, CD4-dependent and CD8-dependent GVHD. However, 
this conclusion was drawn from experiments of a MHC-mismatched GVHD model that led to 
rapid death that was, at least partly, mediated by inflammatory cytokines. In contrast to MHC-
mismatched HCT, recipients of miHAg-mismatched HCT, typically survive the early cytokine-
storm and instead, GVHD primarily manifests by T cell infiltration of target tissues. This 
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phenomenon might be explained by the fact that precursor frequency of alloreactive T cells 
targeting the foreign MHC complex is approximate 100 – 1000 fold greater than in miHAg 
mismatched transplantations. Employing miHAg mismatch models, it could be shown that 
hematopoietic expression of miHAgs is not enough to elicit a CD4-mediated lethal GVHD, 
implicating that non-hematopoietic host cells are critical targets in acute GVHD of miHAg-
mismatched transplantations (Jones et al., 2003). 
In contrast, in a MHC-matched, multiple miHAg-mismatched model CD8+ but not CD4+ T 
cells required cognate interactions with target tissues to mediate GVHD (Matte-Martone et 
al., 2008) and thus the expression of miHAg could theoretically dictate which organs are 
involved in the disease. In accordance with this, it could be demonstrated that different 
miHAgs determine the phenotype, target organ involvement and the kinetics of GVHD 
(Kaplan et al., 2004). MiHAgs are widely expressed, but can differ in their tissue expression 
(De Bueger et al., 1992; Bleakley and Riddell, 2004) and therefore might explain the 
selective organ damage in GVHD. Nevertheless, some identified miHAgs that can cause 
GVHD, such as H-Y antigens (Toubai et al., 2012), are expressed ubiquitously. Taken 
together, the importance of alloantigen expression on epithelial target cells for GVHD still 
remains elusive.  
Yet, if T cells migrate to selective organs (like intestinal tract and skin) although alloantigens 
are expressed and presented ubiquitously, the organ infiltration should be considered as 
antigen independent (Figure 1.3A). Similarly, if T cells selectively infiltrate organs that do not 
express alloantigen, while organs expressing alloantigens remain unaffected, the organ 
infiltration should be considered antigen independent. In contrast, if ubiquitously alloantigen 
expression and presentation would result in a systemic organ infiltration or organ specific 
alloantigen expression would result in the selective infiltration of these organs, might indicate 
that acute GVHD organ infiltration is determined by antigen recognition (Figure 1.3B).  
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Figure 1.3: Does the tissue alloantigen expression and presentation influence the alloreactive T cell 
migration in acute GVHD? (A, B) Different scenarios of T cell migration after total body irradiation might rule out 
the importance of alloantigen presentation in the host tissues. Both scenarios in (A) reflect an antigen 
independent organ infiltration while T cell distribution in sketch (B) describes an antigen dependent organ 
infiltration.  
1.1.7 Antigen-specific transgenic TCR models of GVHD 
Studies from mouse models have been instrumental for the understanding of the cellular 
interactions and development of GVHD. Mouse models of bone marrow transplantation 
involve the transfer of either MHC- or miHAg-mismatched T cells and the GVHD mainly 
affects the skin, gastrointestinal tract, and liver and thereby resembles the tissue tropism and 
further GVHD clinical aspects in humans. The most common conditioning method in mouse 
models of GVHD is total body irradiation. The conditioning ablates the recipient’s bone 
marrow, facilitates the donor stem cell engraftment and prevents the rejection of the grafted 
cells by diminishing recipient T cells and natural killer (NK) cells. The induction of GVHD, 
either to full MHC disparity or to the clinically more relevant miHAg, results in a disease that 
is dependent on either CD8+ T cells, CD4+ T cells, or both. Generally, mouse models of 
GVHD thereby suffer from the difficulty to identify the specific alloantigen that is recognized 
by the responding T cells. This obstacle limits the investigation of antigen-specific donor T 
cell responses within the host. To overcome this limitation, the use of identifiable T cells with 
specificity to a defined antigen causing acute GVHD might be helpful. 
In TCR transgenic mice the specificity of the T cells is restricted to a single peptide epitope 
and therefore allows visualizing antigen specific T cells in vivo. To provoke an antigen 
specific T cell response in the host, the antigen can be either expressed by the recipient or it 
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has to be administered exogenously. TCR-transgenic mice, including H-Y, TEa, 2C, DO11.10, 
and OT-II, were initially generated to study thymic selection, but have recently been used 
studying diverse aspects of GVHD such as the role of antigen affinity (Yu et al., 2006), TREG 
function (Damdinsuren et al., 2010) or cross presentation of antigens in GVHD (Wang et al., 
2011). More recently, using CD8+ T cells from MataHari TCR transgenic mice and CD4+ T 
cells from “Marylin” or “Rachel” transgenic mice, Toubai et al. (2012) demonstrate that the 
recognition of a clinically relevant single H-Y antigen epitope is sufficient to initiate acute 
GVHD. Furthermore, they identified that H-Y expression on recipient stroma, but not on 
recipient hematopoietic cells are critical for GVHD severity (Toubai et al., 2012). TCR 
transgenic Models of GVHD are listed in Table 1.  
Table 1: T cell receptor transgenic Models of GVHD. 
TCR (tg) Recipient strain Antigens T cell dependence Purpose  Reference 
TEa, 2C (BALB/c x C57BL/6)F1 2C, TEa CD4 + CD8 Define effect of host conditioning  
Gonzalez et 
al., 2002 
2C (BALB/c x C57BL/6)F1 2C CD8 
Limited 
repertoire of Ag 
might elict 
GVHD 
Dey et al. 
1999; Yu et 
al. 1999 
B6.H60 B6.H60.Kb-/- H60 CD8 To study cross 
presentation 
Wang et al. 
2011 OT-I B6 actOVA.Kb-/- SIINFEKL CD8 
MataHari C57Bl/6 
H-Y 
CD8 
To define role of 
host APCs in 
GVHD initiation 
Toubai et al. 
2012 Rachel C57Bl/6 CD4 
Marylin C57Bl/6 CD4 
TS1 HA104 Tg S1  CD4 
To define role of 
CD4+ TEM after 
HCT 
Juchem et 
al. 2011 
D10 (B6 x C3H)F1 D10 CD4 
To determine 
alloantigen 
affinity for allo-
response 
Yu et al. 
2006  
 
An extensively studied model antigen in mice is the chicken ovalbumin (OVA) that has been 
widely used in allergy research (Kumar et al., 2010), diabetes (Hänninen et al., 2007) and 
kidney disease (Heymann et al., 2009). TCR transgenic, OVA-specific CD4+ (OT-II) and CD8+ 
(OT-I) T cells recognize the peptides presented respectively by MHC I or II (H-2Kb, C57Bl/6). 
To model type 1 diabetes for example, rat insulin promoter–mOVA (RIP-mOVA) mice 
expressing the model antigen OVA in pancreatic islets have been used to study T cell 
involvement in disease progression. Further transgenic mice exist that express ovalbumin 
tissue specific promotors, such as under the control of a keratin 5 promotor (K5-mOVA), or 
keratin 14 promoter (K14-mOVA) in skin epithelia (Azukizawa et al., 2003; Shibaki et al., 
2004) or under the control of intestinal fatty acid binding promoter (iFABP-OVA) in the small 
intestine (Vezys et al., 2000). Thus, transgenic mouse models have become powerful tools, 
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presenting tissue-specific cognate antigens and T cells with well-defined antigen-specific 
TCRs.  
1.2 Mapping immune processes in intact organs with light sheet 
fluorescence microscopy (LSFM) 
1.2.1 Imaging immune processes 
A variety of different imaging strategies have been utilized to study immune cell activity and 
migration in animal models of human disease. Imaging techniques such as magnetic 
resonance imaging (MRI), positron emission tomography (PET) and single photon emission 
tomography (SPECT) are particularly attractive since they can be readily translated from 
preclinical animal models to clinical application in humans (Gross et al., 2007). Another 
effective method to visualize immune responses in larger specimen is bioluminescence 
imaging (BLI), as 100 – 1000 immune cells can be assessed in vivo. Especially for studies of 
GVHD, where luciferase-expressing T cells can be transplanted, BLI has been proven to 
provide valuable new insights in cell migration and proliferation and ex vivo BLI permitted 
even more precise localization of donor cell infiltrates. However, these techniques generally 
do not provide sufficient resolution to visualize individual cells and in many cases lack 
sensitivity to detect rare biological events in different areas throughout the body. Other 
imaging techniques like confocal microscopy or multi-photon-laser-scanning microscopy 
(MPM) are instructive focusing on pre-selected tissues, but limited in the scope of the areas 
that can be imaged.  
So far, enormous efforts have been undertaken to visualize single immune cells throughout 
the body in murine models of human disease, particularly by high-precision cryosectioning of 
entire organs and subsequent compilation of consecutive images (Reinhardt et al., 2001; 
Machnik et al., 2009). This laborious approach provided valuable insights, however, was 
prone to tissue distortions and artifacts. Recently, several 3D microscopy techniques for 
morphological and functional imaging have been developed to visualize mesoscopic 
specimens such as optical projection tomography (OPT) (Sharpe et al., 2002), optical 
coherence tomography (OCT) (Boppart et al., 1996), and light sheet based techniques such 
as selective plane illumination microscopy (SPIM) (Huisken et al., 2004) or ultramicroscopy 
(Dodt et al., 2007). So far, LSFM has only been employed in very few intact adult mouse 
organs such as the brain (Ermolayev et al., 2009b), spinal cord (Ertürk et al., 2011), or the 
middle ear, (Santi et al., 2009) using single color illumination. Other microscopy techniques 
like OPT and OCT do not achieve cellular resolution (Kumar et al., 2010) or do not allow a 
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multicolor application (Drexler and Fujimoto, 2008). In light-sheet microscopy, a tissue 
clearing procedure (replacement of water by a higher refractive index substance) is typically 
used to make the specimen transparent. Here, to investigate alloreactive T cell trafficking we 
combined deep tissue staining protocols with optimized clearing procedures and advanced 
LSFM for the first time to be used as a quantitative triple-color technique investigating intact 
murine and human samples. Complex immune processes, as for instance in hematopoietic 
cell transplantation or in anti-tumor responses, can now be analyzed on a single cell level in 
large tissues specimens or even entire organs. 
1.2.2 Principal of light sheet fluorescence microscopy 
The principal idea of light sheet based techniques dates back to 1903 and was developed by 
Siedentopf and Zygmondi to observe single gold particles in glasses (Siedentopf and 
Zsigmondy, 1903). In light sheet microscopy a thin light sheet, shaped by a cylindrical lens is 
created to illuminate only a single plane of a specimen. The illumination is established 
orthogonal to the detection axis and thus illumination and detection light paths are completely 
separated from each other. The light sheet is a focused elliptically Gaussian beam that is 
centered and aligned to the focal plane of the detection objective. As all parts above or below 
the light sheet are in the dark, no out-of-focus light contributes to the image and an optical 
sectioning effect is generated. This optical sectioning, in contrast to physical sectioning, 
allows for imaging an intact sample. The dimensions of the light-sheet can be adapted from ~ 
2 μm - 10 μm, depending on sample sizes and employed objective. Images are collected by 
using an objective lens and are finally detected with an electron multiplication CCD (EMCCD) 
camera. To gather three dimensional image stacks the sample is moved stepwise through 
the light sheet in small increments.  
Light sheet fluorescence microscopy has several advantages over other commonly used 
epifluorescence microscopy methods. LSFM profits from a good signal-to-noise-ratio, since 
the thin light sheet generates no out-of-focus illumination. In comparison to raster scanning 
microscopy techniques, such as confocal microscopy or multi-photon microscopy, where 
point or line-scanning is time consuming, LSFM allows imaging the complete field-of-view at 
once, making data acquisition extremely fast. Furthermore, in confocal microscopy the laser 
beam is scanned across the sample to acquire an image, thereby exposing not only the focal 
plane to light, increasing photo-bleaching and photo-toxicity of the sample. Another 
advantage of light sheet microscopy is that it achieves excellent resolution at high 
penetration depths. 
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1.2.3 Modifications and applications of LSFM 
Light sheet fluorescence microscopy techniques already have been used for several different 
biological and biomedical applications. Accordingly, many implementations exist to adapt 
either the mode of light sheet generation, or the sample preparation to improve the imaging 
performance.  
Selective plane illumination microscopy (SPIM) is a light sheet based technique that has 
been used for many applications, especially for developmental research (Figure 1.4, 
(Huisken et al., 2004). This implementation of fluorescence light sheet microscopy is 
optimized for imaging small, live specimens in vivo such as developing embryos of Medaka 
and Drosophila (Figure 1.4C). Especially the high speed image acquisition became important 
for high-resolution fluorescence imaging of live biological specimens (Figure 1.4D). The 
embryos can be kept alive and imaged in a medium-filled chamber for a few days. A unique 
feature of SPIM is the ability to rotate the sample and acquire multiple views that are then 
combined by image processing (multiview fusion) (Swoger et al., 2003, 2007). However, in 
SPIM the parallel light sheet illumination from the side results in shadows and fluorescence 
attenuation caused by the interaction of the excitation light with the biological sample. The 
scattering and absorption in dense life tissue make it difficult to accurately analyze images. 
To overcome such artifacts multidirectional SPIM (mSPIM) has been developed (Huisken 
and Stainier, 2007). In mSPIM the sample is illuminated from two sides with a thinner 
pivoting light sheet created by a laser beam that is scanned over an angle of 10° at a 
frequency of 1 kHz using a mirror. Thus, artifacts, such as shadows and stripes, are markedly 
reduced.  
Ultramicroscopy is another modified light sheet technique that has been developed to image 
large and opaque specimens like adult Drosophila melanogaster, mouse embryos or adult 
mouse brains that are few millimeter in size (Figure 1.3B,E,F, Dodt et al., 2007). Therefore 
the specimen has to be fixed and requires a clearing procedure to become optically 
transparent. During imaging, the sample is retained in the clearing solution. Furthermore, in 
this microscopy set-up two light-sheets are used to illuminate the sample from opposing 
directions, compensating the excitation light attenuation caused by penetrating the sample. 
Providing a more even illumination, this implementation is ideal for the imaging of larger, 
cleared specimens.  
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1.2.4 Development of light sheet generation 
An alternative method to create a light sheet with a cylindrical lens is by rapidly scanning a 
single line focused laser beam during the exposure time. Similar to the pivoting light sheet, 
used in mSPIM, in digital scanned laser light-sheet fluorescence microscopy (DSLM) the 
laser beam is moved up and down to create a plane illumination, as shown by Keller et al. 
2008. The benefit of this technique is the uniformity of the light sheet intensity profile, higher 
illumination efficiency and increased contrast. This modification leads to an improved quality 
of the complex morphology and optical properties of live specimens (Keller et al., 2008) and 
of fixed and cleared tissues. Additional alterations in generating a light sheet promise to 
further increase contrast, generate less image artifacts, and provide even higher resolution, 
such as structured-illumination (Keller et al., 2010), Bessel beam plane illumination 
(Planchon et al., 2011) or even combination of LSFM with STED microscopy (Friedrich et al., 
2011). 
Figure 1.4: Modifications and applications of LSFM.
 (A) Selective plane illumination microscopy (SPIM) and (B) ultramicroscopy are implementations of light sheet 
fluorescence microscopy (LSFM) techniques. Both methods using similar setups (cylindrical lens (cyl), sample 
chamber (ch), objective lens (obj), sample (s), light sheet (side of generation indicated with blue arrows), emission 
(indicated with a green arrow), but light sheet generation and sample preparation are adopted to achieve best 
imaging performance. (C,D) Fish embryos can be imaged with SPIM and revealed (C) different tissues of a 
Medaka embryo after multiview reconstruction (z-Projection, scale 200 µm). (D) High-speed imaging with SPIM 
revealed the heart beats of a Zebrafish expressing fluorescent proteins in myocardium, endocardium and blood 
(Scale 50 µm). (E,F) Ultramicroscopy allows for visualization of (E) whole adult Drosophila (z-Projection, scale 
400 µm) and (F) autofluorescence of the blood vessel system in a mouse embryo (z-Projection, scale 2 mm). 
Sketches and pictures A-F taken from (Huisken et al., 2004; Dodt et al., 2007; Huisken and Stainier, 2009). 
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1.2.5 Sample preparation and adoptions  
Light sheet based microscopy was initially developed for optically transparent objects. 
However, different protocols have been developed to render opaque specimens transparent, 
allowing the successful imaging even deep into adult mouse organs.  
The principle idea of making biological samples transparent is to replace the water of the 
specimen with a liquid of the same refractive index as proteins and lipids (Spalteholz, 1914). 
Typically, differences in the refractive index of bordering components in cells and whole 
organs lead to an opaque appearance, resulting in light scattering effects. For the clearing 
procedure the specimen is classically dehydrated in ethanol and subsequently immersed in a 
solution consisting of a mixture of 1 part benzyl alcohol and two parts benzyl benzoate 
(BABB). This chemical clearing reagent has the same refractive index of proteins. Now intra- 
and extracellular compartments of a specimen have the same refractive indices and light can 
traverse the specimen unhindered, allowing optical imaging deep inside the tissue. Pigment 
bleaching with hydrogen peroxide (Korytowski and Sarna, 1990) or the removing of opaque 
substances, as calcium in bones by EDTA chelation, might further increase the imaging 
quality of certain specimens. Importantly, LSFM is a fluorescent method and therefore, the 
incorporation of fluorescent-labeled molecules (i.e. antibodies) deep within the tissue is 
required to specifically label tissue structures. Optimized protocols are needed to obtain a 
sufficient penetration of fluorescent molecules. 
Further improvements to optimize clearing procedures rendering organs transparent will 
assist to reduce background fluorescence and enhance fluorescent protein stability. For 
some organs, as the murine spinal cord, a tetrahydrofuran-based dehydration procedure was 
shown to be more effective than the use of ethanol (Ertürk et al., 2011). Hama et al. (2011) 
reported about an aqueous reagent, named Scale that rendered biological samples optically 
transparent and completely preserved fluorescent signals in the clarified structures, 
compared to BABB. 
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2 Questions and specific aims 
To understand the mechanisms of T cell migration to selective GVHD target organs appears 
crucial for developing novel strategies to minimize GVHD and to maximize immune 
reconstitution and the GVL effect after allo-HCT. Therefore, this thesis addresses the 
question whether tissue specific alloantigen expression determines T cell migration patterns 
to certain tissues in GVHD. We postulated that if selective organ manifestation in GVHD 
would be dependent on alloantigen expression and presentation, the selective expression of 
alloantigen in different GHVD target and non-target organs would influence the migration of 
alloantigen specific T cells after HCT. To experimentally test this hypothesis, we transplanted 
bone marrow and antigen specific T cells in myeloablative conditioned transgenic mice that 
expressed ovalbumin (OVA) as a model antigen in a tissue-specific manner in GVHD-non-
target organs or expressed OVA ubiquitously in all organs. 
For the detection of first organ infiltrating T cells we set the goal to establish a novel 
microscopy set-up, termed light-sheet fluorescence microscopy (LSFM) a sensitive method 
to visualize and quantify single cells in its biological context by imaging large tissue 
specimens. LSFM emerged as a versatile technique that proved particularly instructive when 
combined with other methods.  
The specific aims of my thesis project were: 
1. To study whether tissue alloantigen expression determines the selective target organ 
manifestation during acute GVHD. 
2. To investigate donor T cell migration patterns after allo-HCT. 
3. To establish an imaging technique that allows for analyzing single cells in large and 
intact tissue specimens. 
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3 Material and Methods 
3.1 Material 
3.1.1 Chemical reagents  
Aceton    Sigma (Deisenhofen, Germany) 
Baytril    Bayer (Leverkusen, Germany) 
Benzyl alcohol   Sigma (Deisenhofen, Germany) 
Benzyl benzoat   Sigma (Deisenhofen, Germany)  
D-Luciferin    Biosynth (Staad, Switzerland) 
Entellan   Merck (Darmstadt, Germany) 
Ethanol    Sigma (Deisenhofen, Germany) 
Fetal Calf Serum (FCS) Invitrogen (Darmstadt, Germany) 
Hexane   Sigma (Deisenhofen, Germany) 
Hydrogen peroxide 30% Sigma (Deisenhofen, Germany) 
Ketamine   Pfizer (Berlin, Germany) 
Methanol    Sigma (Deisenhofen, Germany) 
Normal Rat Serum (NRS) Invitrogen (Darmstadt, Germany) 
O.C.T.    Sakura (Staufen, Germany) 
Paraformaldehyde   Roth (Karlsruhe, Germany)  
Triton X 100   Roth (Karlsruhe, Germany)   
Trypan blue    Sigma (Deisenhofen, Germany) 
Xylazine 2%   CP-Pharma (Burgdorf, Germany) 
3.1.2 Buffers and solutions 
 Lysis buffer (10x): NH4Cl (89.9 g), KHCO3 (10 g), EDTA (0.37 g) in 1000 ml distilled 
water, sterile filtered 
 PBS (10x): NaCl (80 g), Na2HPO4-2H2O (14,2 g), KCL (2 g), KH2PO4 (2 g) in 1000 ml 
distilled water, pH: 6,8  
 Dynal buffer: BSA (0.5 g), EDTA 0.5 M (0.2 ml) in 500 ml (1x) PBS 
 PFA (4%): 4 g PFA in 100 ml (1x) PBS, dissolved at 65°C, pH: 7.4
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 Anesthetics: 8 ml Ketamine (25 mg/ml, Ketanest, Pfizer Pharma, Berlin, Germany), 
2 ml Xylazin (2%) (Rompun, CP-Pharma, Burgdorf, Germany), 15 ml (1x) PBS 
 cRPMI-1640: RPMI-1640 medium supplemented with 10% FCS, Penicillin (100 U/ml), 
Streptomycin (100 µg/ml), L-glutamine (2 mM) and β-mercaptoethanol (50 µM) (all 
Invitrogen, Darmstadt, Germany) 
3.1.3 Antibodies and secondary reagents 
Table 2: Murine primary antibodies used for FACS staining and fluorescence microscopy. 
Antibody Clone Conjugation Isotype Purchased from 
CD11c N418 Alexa488 or PE armenian hamster Biolegend 
CD19 6D5 APC, biotin, PE rat Biolegend 
CD21/35 7E9 APC rat Biolegend 
CD31 MEC13.3 biotin rat Biolegend 
CD31 390 biotin rat Biolegend 
CD3ε 145-2C11 purified armenian hamster BD Pharming 
CD4 RM4-5 Alexa488, APC, APC-CY7 or PE rat Biolegend 
CD4 GK1.5 Alexa647 rat Biolegend 
CD44 IM7 Pacific Blue rat Biolegend 
CD45.1  A20 Alexa647, APC-Cy7, PE mouse Biolegend 
CD45.2 104 Alexa647, APC-Cy7, FITC mouse Biolegend 
CD62L MEL-14 APC-CY7 rat Biolegend 
CD8α 53-6.7 Alexa488, APC, APC-CY7, biotin or PE-CY7 rat Biolegend 
CD8α 53-6.7 FITC or PE rat eBioscience 
CD90.1 OX-7 Alexa488, Alexa647 or FITC mouse Biolegend 
CD90.1 HIS51 APC or biotin mouse eBioscience 
CD90.2 30-H12 biotin, FITC or PE rat Biolegend 
IL2 JES6-5H4 Alexa647 rat eBioscience 
IFN-γ XMG1.2 Brilliant Violet 412 rat Biolegend 
Insulin polyclonal unconjugated Guinea Pig Dako 
Lyve-1 ALY7 eFluor 660 rat eBioscience 
MAdCAM-1 MECA-367 Alexa488, biotin rat Biolegend 
OVA257-264 
peptide bound to 
H-2Kb 
25-D1.16 biotin mouse eBioscience 
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Secondary antibodies: Donkey anti goat CY3 purchased from Dianova (Hamburg, Germany), 
goat anti mouse IgG AlexaFluor® 568 purchased from Invitrogen (Karlsruhe, Germany). 
Secondary reagents: Streptavidin-conjugated AlexaFluor® 488, AlexaFluor® 532, 
AlexaFluor® 546, AlexaFluor® 568 or AlexaFluor® 647 all purchased from Invitrogen 
(Karlsruhe, Germany). 
3.1.4 Commercially available kits 
CFSE Cell Proliferation Kit    Invitrogen (Karlsruhe, Germany) 
Avidin-Biotin blocking Kit  Vector Laboratories (Burlingame, CA) 
Vektashield mounting medium       Vector Laboratories (Burlingame, CA) 
Dynabeads® Magnetic Beads   Invitrogen (Karlsruhe, Germany) 
Cytometric Bead Array    BD Bioscience (Heidelberg, Germany) 
3.1.5 Consumables 
6 well flat bottom culture plates      Greiner Bio-One (Frickenhausen, 
Germany) or Sarstedt (Newton, USA) 
96 well flat bottom culture plates        Sarstedt (Newton, USA) 
96 well U bottom culture plates        Sarstedt (Newton, USA) 
96 well V bottom culture plates        Sarstedt (Newton, USA) 
5, 15 and 25 ml single use pipettes      Greiner Bio-One (Frickenhausen, 
Germany) 
10 µl tips                Sarstedt (Newton, USA) 
200 µl tips              Sarstedt (Newton, USA) 
1000 µl tips       Sarstedt (Newton, USA) 
15 ml and 50 ml centrifuge tube      Greiner Bio-One (Germany) 
Cell strainer 70 µm             BD Biosciences (CA, USA) 
Cryomolds      Sakura (Staufen, Germany) 
SuperFrost Microscope Slides  R. Langenbrinck (Emmendingen, 
Germany) 
U-100 Insulin Syringes     BD Bioscience (Heidelberg, Germany) 
5, 10 and 15 ml Syringes     BD Bioscience (Heidelberg, Germany) 
Glucose test stripes FreeStyle Lite®  Abbott (Wiesbaden, Germany) 
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3.1.6 Mice 
BALB/C and C57BL/6 mice between 8 and 12 weeks old were purchased from Charles River 
Laboratories (Sulzfeld, Germany).  
Following (transgenic) mice included in the study were bred in our own mouse colony at the 
Center for Experimental Molecular Medicine (ZEMM) Würzburg: 
Table 3: Mice 
Scientific name Transgene Coat color Short name 
C57Bl/6.L2G85.CD90.1  Luciferase black B6.L2G85.CD90.1 
C57Bl/6.L2G85.CD45.1  Luciferase black B6.L2G85.CD45.1 
C57Bl/6.L2G85.DsRed  Luciferase, Ds Red black B6.L2G85.DsRed 
C57BL/6.L2G85.OT-I.Ragko.CD45.1  OT-I TCR, Luciferase black B6.L2G85.OT-I.Ragko.CD45.1 
C57BL/6.L2G85.OT-I.Ragko.CD90.1  OT-I TCR, Luciferase black B6.L2G85.OT-I.Ragko.CD90.1 
C57BL/6.L2G85.OT-II.Ragko OT-II TCR, Luciferase black B6.L2G85.OT-II.Ragko 
C57BL/6.L2G85.OT-II.Ragko.CD45.1  OT-II TCR, Luciferase black B6.L2G85.OT-II.Ragko.CD45.1 
C57BL/6-Tg(ACTB-OVA)916Jen/J  beta actin OVA albino, black B6a.βa-Ova or βa-Ova 
C57BL/6-Tg(Ins2-TFRC/OV)296Wehi/WehiJ RIP-mOVA albino, black B6a.ins.ova or RIP-mOva 
C57BL/6J-Tyrc-2J/J none albino B6.a 
 
 
Briefly, transgenic mice B6.L2G85.CD90.1 expressing firefly luciferase (luciferase+) were 
generated by backcrossing the luciferase+ FVB/N-L2G85 founder line (Cao et al., 2004; 
Beilhack et al., 2005) with the C57Bl/6 mice for more than 12 generations. Further transgenic 
mice expressing luciferase B6.L2G85.CD45.1 and B6.L2G85.DsRed, which additionally 
express the fluorescent protein DsRed, were bred in our colony. B6.L2G85.OT-
I.Ragko.CD45.1 and B6.L2G85.OT-I.Ragko.CD90.1 mice were generated by crossing 
B6.L2G85.CD45.1 or B6.L2G85.CD90.1 with OT-I mice purchased from Jackson Laboratory 
(Jackson laboratory reference: C57BL/6-Tg(TcraTcrb)1100Mjb/J) and B6.Rag deficient mice 
(B6.129S7-Rag1tm1Mom/J). OT-I mice carry a transgenic CD8+ T cell receptor specific for the 
ovalbumin derived peptide 257-264 (SIINFEKL) in the context of H-2Kb. B6.L2G85.OT-
II.Ragko and B6.L2G85.OT-II.Ragko.CD45.1 were created by crossing B6.L2G85 or 
B6.L2G85.CD45.1 with OT-II mice purchased from Jackson Laboratory (Jackson laboratory 
reference: C57BL/6-Tg(TcraTcrb)425Cbn/J and B6.Rag deficient mice (B6.129S7-
Rag1tm1Mom/J). OT-II mice have a transgenic CD4+ T cell receptor specific for the ovalbumin 
derived peptide 323-339 presented in the context of the MHC class II. The transgenic strain 
B6a.βa-Ova (Jackson laboratory reference: C57BL/6-Tg(ACTB-OVA)916Jen/J expresses 
ubiquitously the membrane bound chicken ovalbumin (OVA) gene under the chicken beta 
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actin promoter. B6a.ins.ova mice express membrane bound OVA under the control of the rat 
insulin promoter (Ins2) (Jackson laboratory reference: C57BL/6-Tg(Ins2-
TFRC/OV)296Wehi/WehiJ also termed “RIP-mOVA”). OVA expression is detectable in 
pancreatic beta cells, kidney proximal tubular cells and a weak expression in the testis. For 
improved in vivo bioluminescence imaging of luciferase transgenic OT-1 and OT-2 T cells we 
backcrossed both OVA expressing mouse strains to the B6 albino background (C57BL/6J-
Tyr<c-2J>). 
Before each experiment, all transgenic animals were genotyped with PCR or phenotyped by 
flow cytometry (exclusion of existing B cells in the peripheral blood of B6.L2G85.OT-
I.Ragko.CD45.1, B6.L2G85.OT-I.Ragko.CD90.1, B6.L2G85.OT-II.Ragko and B6.L2G85.OT-
II.Ragko.CD45.1 mice. All studies were performed under institutional approval according to 
specific animal use protocols. 
3.2 Methods 
3.2.1 Single cell suspension from spleen and lymph nodes  
Organs were removed from mice, cut into pieces and homogenized by gently smashing 
through a cell strainer. The cell strainer was rinsed with 8 ml Lysisbuffer into a 50 ml 
centrifuge tube. Erythrocytes were lysed by incubating the cells in Lysisbuffer for 2 minutes 
(min) at room temperature. After adding 10 ml PBS the cells were centrifuged at 1500 rpm for 
5 min at 4ºC. The supernatant was removed and the pellet was resuspended in PBS. If 
required (e.g. for transplantation or FACS sorting) the cells were again passed through a cell 
strainer before counting. 
3.2.2 Single cell suspension from organs using enzymatic digestion 
Organs were removed from mice and kept in cold PBS. Subsequently, tissues were cut 
mechanically in small pieces followed by an enzymatic digestion in PBS (Mg+, Ca+) with 
2 mg/ml collagenase D and 0.1 mg/ml DNaseI at 37°C for 30 min. The cell suspension was 
smashed through a cell strainer, and rinsed with PBS + 0.5% BSA.  
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3.2.3 Multicolor flow cytometry 
Fluorescence activated cell sorting (FACS) analysis was performed on single-cell 
suspensions using a BD FACSCantoII flow cytometer (BD Bioscience, Heidelberg, 
Germany). 
For analysis of primary mouse cells the single cell solution was transferred to a 96 well plate 
or FACS tubes. To block unspecific binding to Fc receptor cells were incubated with NRS 
(1:10) for 5 min in the fridge. The cells were stained with primary fluorochrome labeled 
antibodies for 30 min in the fridge and subsequently centrifuged for 5 min at 1500 rpm. The 
pellet was resuspended in PBS and dead cells were excluded by propidium iodide staining 
approximate 5 min before FACS. A maximum of 8 colors was analyzed at a single sample. To 
compensate for the spillover in the emission spectrums for each fluorochrome, a control cell 
suspension or antibody capture beads were individually stained with single fluorochrome 
labeled antibody also used in the multiple staining. This compensation procedure (Tung et 
al., 2004) allowed calculating and subtracting the appropriate overlap to yield the specific 
signal intensity for each fluorochrome. To set gates in multicolor stained samples the 
fluorescence minus one (FMO) method (Herzenberg et al., 2006) was performed. In this 
gating control strategy the samples were stained with all fluorochromes, but one 
fluorochrome at a time. All antibodies were titrated for optimal performance before their 
application. Used antibodies are listed (see antibodies 3.1.3). Acquired FACS data was 
analyzed with FlowJo software (Tree Star, Ashland, OR). 
3.2.4 Magnetic bead-based cell separation  
Dynabeads® Magnetic Beads CD8 or CD4 positive, CD8 or CD4 negative or T cell negative 
Isolation Kits (Invitrogen Karlsruhe, Germany) were used either to deplete or to enrich T cells 
from a single cell suspension. Sample preparation was according to the manufacturer 
instructions. The purity of the enrichment was analyzed with FACS. 
3.2.5 FACS based cell separation 
Magnetic bead pre-enriched T cells were further sorted to pure CD8+ or CD4+ T cells or 
further into CD4+CD44hiCD62Llo effector memory, CD4+CD44hiCD62Lhi central memory and 
CD4+CD44loCD62Lhi naïve T cell subsets using a FACSAria III cell sorter (BD Bioscience, 
Heidelberg, Germany). The post sort purity is given in the respective experiment. 
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3.2.6 Hematopoietic cell transplantation 
Recipient mice were conditioned with a single total body irradiation dose of 8 Gy (BALB/C) or 
9 Gy (C57BL/6) using a Primus1 (Siemens, Erlangen, Germany) or a MX20 LX60 irradiator 
(Faxitron Bioptics, Much, Germany). For hematopoietic reconstitution, mice were 
intravenously injected (into the orbital cavity) with 5 x 106 sex- and age-matched bone 
marrow (BM) cells within 2 hours (h) after radiation. To induce acute GVHD allogeneic 
enriched T cells or splenocytes were coinjected intravenously. The specific numbers of 
transferred T cells are stated for each experiment. Preferably mice at the age of 8 to 12 
weeks were used for hematopoietic stem cell transplantation experiments. 
3.2.7 Blood glucose 
One small drop of blood was gained by carefully cutting the tail vein of the mouse with a 
scalpel. Blood glucose was measured in mg/dl using a FreeStyle Freedom Lite® (Abbott, 
Wiesbaden, Germany) blood glucose monitoring system with the appropriate FreeStyle Lite® 
diagnostic medical dipsticks. The test stripes were dipped into the drop of blood until an 
acoustic sound signaled the end of the measurement. Monitoring of the different groups was 
always to the same time of day and mostly before 12 a.m. The systems measurement range 
of glucose levels is between 20 - 500 mg/dL (1.1 - 27.8 mmol/L). Consequently, values stated 
as low (lo) had to be listed with 20 mg/dl and values stated as high (hi) were listed with 
500 mg/dl. 
3.2.8 Chimeras 
Chimeras were created by hematopoietic reconstitution with 10 x 106 T cell depleted BM cells 
injected i.v. within 2 h after radiation. Reconstituted mice were analyzed for chimerism by 
flow cytometry analysis of the blood and used for experiments after 1-3 months. All animal 
studies were performed under institutional approval according to specific animal use 
protocols. 
3.2.9 Bioluminescence imaging (BLI)  
In vivo bioluminescence imaging was performed using an IVIS Spectrum CCD-imaging 
system (Caliper Xenogen, Alameda, CA). Mice were anesthesized with an intraperitoneally 
injected mixture of Ketamine (50 µg/g body weight) and Xylazine (5 µg/g body weight) in 0.1 
M Phosphate-Buffered Saline (PBS) in a total volume of 10 µl/g body weight. D-Luciferin was 
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injected in a concentration of 150 µg/g body weight and images were taken 10 min after 
injection and allowed identification of cell proliferation and migration (Figure 3.1). 
To perform ex vivo imaging mice were either injected with the same mixture of anaesthetic 
and luciferin or directly after in vivo BLI with an additional dose of luciferin (150 µg/g body 
weight) only. Accordingly, 10 or 5 minutes after injection, mice were euthanized and organs 
were removed within 3 min. Ex vivo bioluminescence images provided higher resolution of 
selective organ signal distribution. Samples were stored in PFA or embedded in TissueTec or 
for further histological analyses. Imaging data were analyzed with Living Image ® 4.0 
(Caliper, Xenogen).  
Figure 3.1: Scheme for set regions of 
interest (ROIs) to quantify BLI 
measurements (in vivo and ex vivo). (A) 
Photograph of a mouse with arrows roughly 
indicating the location of selected organs. In 
combination with the BLI image the photo 
allows to identify the localization of 
transplanted luciferase+ cells in vivo. (B) 
Arrangement of explanted organs for ex vivo 
BLI. Cervical lymph node (cLN), thymus (thy), 
heart (hrt), lung (lu), kidney (kid), inguinal 
lymph node (iLN), liver, gastrointestinal tract 
(GIT), small bowel (sb), mesenteric lymph 
nodes (mLN), large bowel (lb), pancreas 
(panc), and spleen (spl).  
3.2.10 Immunofluorescence microscopy (IFM) 
Tissue samples were embedded in O.C.T. within cryomolds and cryopreserved at -20°C. 
Frozen sections of 5 µm thickness were mounted on microscope slides and stored at -20°C. 
The sections were initially thawed for 10 min at room temperature (RT). After acetone fixation 
(7 min at RT) and air drying (2 min), sections were washed in PBS (3x 5 min) and incubated 
with blocking solution (PBS + 2% FCS) for 15 min. If required samples were incubated with 
an Avidin-Biotin blocking Kit for 15 min each. Incubations with primary antibodies were 
performed for 1 h at RT and samples were washed in PBS (3x 5 min). Samples were 
incubated with secondary antibodies or streptavidin labeled fluorophores for 30 min at RT 
and washed in PBS (3 x 5 min). Used antibodies are listed (antibodies section). Nuclei were 
stained with DAPI (4',6-diamidino-2-phenylindole) in a dilution of 1:3000 for 5 min at RT and 
washed again in PBS (3 x 5 min). Samples were coated with mounting medium for 
fluorescence (Vectashield, Vector Laboratories, Burlingame, CA), covered with cover slips 
and sealed. Fluorescence microscopic evaluation was performed on a Zeiss microscope 
(Axio Imager.M1, Zeiss, Jena, Germany). Standard objectives were 10x with numerical 
MATERIAL AND METHODS 
36 
 
aperature (NA) 0.25, 20x with NA 0.8 or 40x with NA 1.3 oil. Images were processed using 
AxioVision 4.8 (Zeiss, Jena, Germany) or ImageJ (US National Institutes of Health, Maryland, 
USA). 
3.2.11 Confocal microscopy  
Tissue samples prepared for LSFM were placed into a three-dimensional self-constructed 
chamber filled with clearing solution. The chamber consisted of high quality steel threaded 
rings (diameter 3.5 mm) separating two round cover slides (approx. 500 µm in height and 
300 – 400 µl volume). Serial confocal Z-stacks were taken with an increment of 2 µm on a 
Leica SP5 laser-scanning confocal microscope (Leica, Mannheim, Germany) with a 20x (NA 
0.7) immersion objective. The fluorescence emission resulted from excitation from a 633 nm 
laser and was detected with 680-720 nm spectral bandwidth on Leica TCS SP5 scanner and 
LAS AF software (Leica, Mannheim, Germany). 
3.2.12 Multi-photon-laser-scanning microscopy (MPM) 
Samples were embedded into a self-constructed chamber for MPM. MPM was equipped with 
an optical parametric oscillator (OPO, APE) for two-photon excitation at 1100 nm. The 
excitation beam was focused with a 20x NA 0.95 water objective (Olympus). Emission was 
detected with HQ535/50nm, HQ605/70nm and HQ710/75nm filter. Sequential 3D stacks 
were obtained for up to 1 mm penetration depth at a step size of 5 µm. Single color image 
stacks (overlap 16%) were stitched together, image size was reduced from 5566 x 3768 pixel 
to 756 x 512 pixels and photomultiplier tube (PMT) induced noise outliers were removed with 
ImageJ (processing package Fiji, US National Institutes of Health) before 3D image 
processing with Volocity (PerkinElmer). 
3.2.13 Light sheet fluorescence microscopy setup 
We used a LSFM setup similar to a previously described setup (Ermolayev et al., 2009b), 
however the sample was illuminated from one side by various laser sources: 405 nm diode 
Laser (56ICS025 Melles Griot), 473 nm DPSS laser (MBL-473 100 mW, CNI), 532 nm DPSS 
laser (MGL-W532 500 mW, CNI) and 639 nm diode laser (Cube 640-40, Coherent). An 
objective inverter (LSM Tech, Stewartstown) on a commercial inverted microscope 
(Axiovert 200, Zeiss) allowed a flexible horizontal positioning of the objective at a greater 
distance and range than typically possible on an inverted microscope. The laser excitation 
beams (3-4 mm diameter) were expanded 3-fold with a telescope (Thorlabs). With focus 
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beam waist of 4 to 9 µm a ca. 1 cm tall light sheet was created by focusing the beam in a 
cylindrical lens (f=5 cm and f=3.6 cm, Newport) depending on the detecting objective lens 
(Apochromat 5x with 0.16 NA and LD Achroplan 20x with 0.4 NA objectives (Zeiss)). The 
beam light sheet was adjusted exactly along the focus plane of a microscope. Fine focusing 
of the light sheet on the specimen was performed by moving the cylindrical lens mounted on 
a translation stage (Standa).  
After sample fixation and clearing (see Sample Preparation), the specimen was affixed with 
Pattex acryl amide glue (Henkel) to a home made glass rod and placed in a home made 
cover glass chamber filled with clearing solution. The sample was positioned with a stepper 
motor-controlled stage (Standa). The stage with a feedback-memory system enabled 
translational and rotational step motion with accuracy of 0.1 µm and 0.1 degrees, 
respectively.  
The fluorescence emission light was filtered using a motorized filter wheel (Standa) 
according to the excitation wavelength: DAPI 405 nm HQ440/40, Alexa Fluor® 488 
(Invitrogen) 488 nm HQ525/50, Alexa Fluor® 532 (Invitrogen) HQ605/75; Alexa Fluor® 647 
(Invitrogen) 640nm HQ695/55 (all Chroma). Fluorescence was detected by a back-
illuminated electron multiplying charge-coupled device (EMCCD) camera (512 x 512 pixels, 
16 µm/pixel Cascade II, Photometrics). Exposure times for image acquisition were 200 – 
500 ms per frame. To acquire the complete image stack each excitation wavelength and 
emission filter combination were used sequentially plane by plane. We used the software 
package LabView (National Instruments, Austin, TA, USA) to control all hardware including 
the synchronization with data acquisition software MetaMorph 7.1 (Molecular Devices, 
Downingtown, PA, USA). Finally, the individual color stacks were overlaid via image 
processing using Volocity Software package (Improvision, Coventry, Great Britain). 
3.2.14 Alterations of the primary LSFM setup 
To further improve LSFM a resonant optical scanner SC10 (Electro Optical Products Crp., 
New York, USA) was implemented allowing for scanning the light sheet (Huisken and 
Stainier, 2007; Keller et al., 2010) with an angel of 20 degree and a frequency of 1 kHz. This 
method successfully reduced shadowing effects in the pictures.  
3.2.15 Image acquisition by LSFM  
Multiplexed and multicolor images were acquired in two different steps. First, each color 
channel was acquired separately. The individual color stacks were superimposed using 
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Volocity Software package (Improvision, Coventry, Great Britain). Between each stack the 
appropriate laser wavelength was triggered by the camera. The emission filter turret position 
in the microscope was manually adjusted. Second, each plane of a stack was imaged 
sequentially by each wavelength and emission filter combination. Resulting multi-color stacks 
were processed on Volocity software. Exposure times for image acquisition were 200 or 
500 ms per frame. The excitation wavelengths, emission filter colors and camera acquisition 
were synchronized by LabView Software (National Instruments, Austin, TA, USA) via TTL 
pulses provided by I/O board (ME-RedLab, Meilhaus GmbH, Puchheim, Germany) to the 
CCD camera and to the motorized filter wheel. Data acquisition and storage were 
synchronized as well by LabView and administered using the software package MetaMorph 
7.1 (Molecular Devices, Downingtown, PA, USA). 
3.2.16 Image processing 
Resulting multicolor stacks were processed, if necessary (e.g. cropped, reduced), with 
ImageJ (US National Institutes of Health). Subsequently, we used the 3D image processing 
software Volocity (Improvision, Coventry, Great Britain) to prepare the individual images and 
videos and developed algorithms to automate cell counting and volume calculations. 
3.2.17 Volume calculations and automated cell counting 
Multicolor stacks were processed on Volocity software (Improvision, Coventry, Great Britain) 
for 3D rendering and subsequently volume quantification and cell counting. We calculated 
volumes of autofluorescence, MAdCAM-1 and clustered donor T cells (Volocity 
Measurements: Find objects using intensity > Clip objects to ROI) within a 3D ROI fitted to 
border the whole Peyer’s patch. Lower limit of specific threshold intensity was calculated with 
ImageJ by the mean of 10 individual threshold measurements for each individual sample. For 
automated cell counting we used following algorithm (Volocity Measurements: Find objects 
using intensity > Exclude objects touching edge of image > Exclude objects by size > Filter 
Measurements: Standard deviation). The lower limit of the object size was set to 400 µm2 as 
calculated before. We used a lower limit of the standard deviation ranging from 250-500 to 
ensure automated event identification. Mathematical analysis was performed with Excel 
(Microsoft) and statistical analysis with Prism 5 (GraphPad Software, San Diego, CA, USA). 
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3.2.18 Preparation and clearing of mouse specimens for LSFM 
Organs were prepared for LSFM by modified protocols of previously described procedures 
(Spalteholz, 1914; Dodt et al., 2007). Briefly, mice were anesthetized by intraperitoneal 
injection of Ketamine-Xylazine and transcardially perfused with 20 ml ice-cold PBS followed 
by 40 ml of 4% paraformaldehyde (pH 7.4). Following the perfusion, organs were removed. 
The samples were placed and stored in paraformaldehyde for at least 2 h at 4°C until further 
procedure. Hemoglobin rich organs were bleached for 30 min in 15% hydrogen 
peroxide/methanol to brighten optically dark structures. For homogenous immuno-
fluorescence of large specimens ex situ, the tissue samples were blocked for 18-24 h with 
2% FCS/PBS in 0.1% Triton-X and afterwards incubated with the respective antibodies for 24 
h at 4°C on a shaker. Samples were washed 3 times in PBS for 1 h and if required incubated 
with streptavidin or secondary antibodies labeled with fluorochromes for another 24 h and 
washed again 3 times  in PBS for 1 h. To clear specimens the tissue was dehydrated in a 
graded ethanol series (30%, 50%, 70%, 80%, 90%, 96% and in 100% for 2 h each) at room 
temperature. After rinsing the samples for 2 h in 100% n-hexane (Sigma, Munich, Germany), 
the n-hexane was replaced stepwise by a clearing solution consisting of 1 part benzyl alcohol 
in 2 parts benzyl benzoate (Sigma, Munich, Germany). Air exposure was strictly avoided at 
this step. Tissue specimens became optically transparent and suitable for the LSFM imaging 
after incubation in the clearing solution for at least 2 h at room temperature.  
3.2.19 Antibody intravenous staining 
Alternatively to ex situ antibody staining fluorochrome labeled antibodies were injected 
intravenously (i.v.) 2.5 h (300 µg CD4, CD45.1, CD90.1 or CD11c) or 0.5 h (50 µg  
MAdCAM-1) before euthanizing the mice. Organs were removed and prepared for 3D 
microscopy. To confirm distribution and specificity of i.v. antibody staining additional post-
section staining was performed with the same antibody. To demonstrate antibody distribution 
and specificity of inflamed and non-inflamed tissues, CD4-Alexa647 antibody was injected in 
untreated mice or in mice at day+6 after allo-HCT. 2.5 h later mice were euthanized and 
spleens and PPs were harvested and digested according to a previously described protocol 
(32) with slight modifications. Briefly, organs were digested (2 mg/ml collagenase D and 0.1 
mg/ml DNaseI) at 37°C for 30 min in the presence of saturating amounts of CD4-FITC 
antibody (30 µg/ml) to prevent an ex post staining of remaining unbound CD4-Alexa647. 
Thus, CD4-FITC single positive cells indicated ex situ stained cells. If not specifically 
indicated as antibody i.v. staining, fluorescence staining was performed according to the ex 
situ staining protocol.  
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3.2.20 Preparation of human tissue for LSFM 
The preparation of human samples was similar to mouse tissue preparation with important 
modifications for dense human specimen. Fresh biopsy tissue was fixed for 2-4 h in PFA 
washed in PBS, bleached in 15% hydrogen peroxide/methanol and again washed in PBS. 
Subsequently the sample was pretreated with 0.1% Triton-X/PBS for 24 h before adding 2% 
FCS for another 8 h. To allow for homogenous staining of deeper tissue layers antibody 
incubation was performed for 4-6 d in 0.1% Triton-X/PBS. After washing again in PBS the 
sample was dehydrated in a graded ethanol series for 4 h each. The clearing procedure was 
performed exactly to the preparation of mouse tissue. All biopsies were obtained for 
diagnostic purposes and the study was approved by the Ethics Committee of the Medical 
Faculty, University of Würzburg, Germany. 
3.2.21 Mixed lymphocyte reaction (MLR) 
To analyze proliferation capacity and cytokine production of OT-I T cells in vitro, cells were 
either stimulated by irradiated ovalbumin expressing cells or by TCR stimulation. Effector 
cells (OT-I) were mixed with irradiated (20 Gray) splenocytes from βa-Ova mice in a ratio of 
1:4. For maximal T cell stimulation, TCRs were stimulated by adding CD3ε (30 ng/ml) and  
IL-2 (26.5 IU/ml) to cRPMI medium. Cells were maintained in 200 µl cRPMI medium in a 96-
well round-bottom plate. After 96 h, T cell proliferation and cytokine production was analyzed 
by flow cytometry. 
  
 
4 Results 
4.1 Mapping immunological processes in intact organs using LSFM 
4.1.1 A virtual journey through intact tissues by advanced multicolor LSFM 
Using LSFM we imaged Peyer's patches (PPs) that are initiation sites for adaptive immune 
responses as they occur in infections and autoimmune diseases and in GVHD. We visualized 
intact PPs of adult mice after specific deep-tissue antibody staining and clearing of the tissue 
specimens (Figure 4.1A,B).  
Three spectrally distinct light sheets were created for a one-sided illumination and images 
were detected sequentially (Figure 4.1C). Intrinsic autofluorescence in the green color 
channel provided microanatomical details of the intestinal mucosa and submucosa. Even 
subepithelial dome regions and B cell follicles of PPs could be visualized and clearly 
differentiated from adjacent crypts and villi. To highlight T lymphocytes we stained with red 
labeled anti-CD4-Alexa647. High endothelial venules (HEVs), that play an important role for 
lymphocyte entry to PPs, were labeled with mucosal addressin cell adhesion molecule-1 
(MAdCAM-1-Alexa546, measured in the yellow color channel). High precision optical z-
stacks provided 1800 optical sections (5x objective) with an increment of 5 µm and allowed 
for scanning of whole PPs and lymph nodes (LNs) (size > 18 mm3) in three color channels 
within minutes. The resulting z-stack required no further image processing and could be 
directly used for 3D tissue reconstruction (Figure 4.1D,E), volume measurements and 
quantification of protein expression. This precise 3D tissue reconstruction additionally 
allowed a virtual journey through the small intestine, which offers unique insights into the 
whole PP including adjacent areas (Supplemental Video 1,2). Using a 20x objective enabled 
us to visualize single CD4+ cells (Figure 4.1F) and even subcellular components, such as 
individual nuclei (Figure 4.1G), deep within the tissue. In our hands, LSFM has proven to 
have a major acquisition speed advantage over Multi-photon microscopy (MPM) in imaging 
whole transparent PPs (LSFM < 12 min, MPM approx. 6 h) and reached a higher penetration 
depth (LSFM > 2 mm). In our hands, LSFM has proven to have a major acquisition speed 
advantage over MPM in imaging whole transparent PPs (LSFM < 12 min, MPM approx. 6 h) 
and reached a higher penetration depth (LSFM > 2 mm). 
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Figure 4.1: Principal of optical sectioning and computational 3D reconstruction by multicolor 
LSFM. (A) The sample is placed into the chamber with clearing solution and illuminated by laser light-
sheets of different wavelengths to excite and detect fluorescence (beam path of emission and excitation is 
indicated by an arrow) in the labeled specimen in three detection channels by turning an optical filter 
wheel. To create optical z-stacks, the sample is moved by 1-5 μm increments through the light-sheet. 
Assembling X-Y-Z planes allows computational 3-dimensional reconstruction; (B) gut associated PPs are 
important sites of mucosal immune reactions. (C) Imaging of tissue autofluorescence (green) allows for 
visualization of micro-anatomical features of intact organs such as the small intestine containing a PP with 
high endothelial venules (MAdCAM-1, cyan) and CD4+ T cells (red) as single and color-merged single 
optical sections; objective, 5x; scale bar, 100 μm, and (D) after computational 3D reconstruction; (E) 3D 
reconstruction of the whole organ reveals co-localization of MAdCAM-1 expression and CD4+ T cells in a 
PP. Using a 20x objective allowed a higher magnification of (F) single CD4+ T cells (z-Projection Scale 
bar, 100 μm) and (G) subcellular precision imaging single cell nuclei (stained with DAPI) within lymph 
nodes (z-Projection Scale bar, 100 μm).  
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4.1.2 Application of LSFM in multiple murine and human tissues 
Labeling of intact tissues with multiple fluorescent antibodies for 3D imaging opens a broad 
range of biomedical applications because any molecule of interest can be stained. For 
optimal analysis of whole organs a homogeneous and specific antibody staining deep into 
the tissue is required. To this end two strategies turned out to be efficient. We injected 
fluorochrome labeled antibodies intravenously (i.v.) and shortly thereafter, euthanized 
animals for microscopic analysis. We confirmed the specificity of antibody binding and 
distribution with immunofluorescence microscopy on frozen sections and by flow cytometry 
(see section 3.1.2.1 Deep tissue antibody staining). Alternatively, we optimized a protocol to 
stain fixed intact organs that allowed for deep tissue staining. Only the combination of deep 
tissue antibody staining with sample clearing procedures allows visualizing any individual 
fluorescently labeled cell type within various mouse tissues such as the heart, testicle, skin 
and lymph nodes (Figure 4.2A-C). After the clearing procedure, most tissue specimens 
became optically transparent and suitable for the imaging with LSFM. The successful 
imaging of hemoglobin rich heart and optical dense liver required extra tissue brightening by 
peroxidase treatment before sample clearing. In addition to studies in the mouse we applied 
LSFM to analyze human specimens such as tonsils and colon cancer biopsies. Here, we 
successfully stained and displayed CD8+ T cells in relation to CD31+ endothelial cells in 
tonsils (Figure 4.2D) and tumor infiltrating CD4+ and CD8+ T cells in colon cancer (Figure 
4.2E). Of note, the desmoplastic stroma reaction that is often present in cancer samples 
required to modify the processing procedure to allow antibody access into these very dense 
tissues.  
4.1.2.1 Deep tissue antibody staining  
For deep tissue antibody staining in fixed organs several critical steps turned out to be 
important to achieve good results. We avoided over-fixation of the tissues, as the PFA 
increases the antigen masking we performed short timed post fixation, if possible. The 
pretreatment of the fixed organs up to 24 h with Triton-X, turned out to enhance antibody 
penetration. Specimens were processed in pieces of max. 1.5–2 cm. Normally, for mouse 
tissues an antibody staining of 1d was sufficient to fully penetrate the specimen. To 
guarantee antibody access into dense human tissues, antibody incubation was performed for 
4-6 d. The long time staining was performed on a shaker to avoid antibody sedimentation.  
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Some antibodies did not work in the PFA fixed tissues, thus we established tissue staining 
protocols by injecting antibodies intravenously. Antibodies were injected i.v. 2.5 h (CD4, 
CD11c) or 0.5 h (MAdCAM-1) before perfusion. After injection, antibodies should distribute 
via the bloodstream and diffuse to peripheral tissues. To confirm distribution and specificity of 
 
Figure 4.2: Multicolor LSFM of diverse murine and human tissues.
(A-C) A C57Bl/6 mouse was injected i.v. with fluorescent labeled antibodies CD31 (cyan) and LYVE-1 (red). 
Organs such as (A) heart, (B) testicle and (C) skin were removed 1 h after injection and prepared for LSFM. 
Shown are 3D reconstructions from optical sections imaged with a 5x objective. (D,E) LSFM allowed imaging of 
whole human tissue biopsies after modifying the processing procedures. (D) z-Projection of a human tonsil biopsy 
(autofluorescence, green) shows the co-localization of CD31 (red) and CD8 (cyan) (Scale bar: 500 µm). (E) A 
moderate differentiated human colon adenocarcinoma specimen with tumor infiltrating CD8+ T cells (red) and 
CD4+ T cells (cyan) (Scale bar: 500 µm).  
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antibody injected intravenously (i.v) staining sections of several organs from an untreated 
mouse were compared to sections from mouse intravenously injected with fluorescent 
labeled antibodies (MAdCAM-1, CD11c and CD4) by conventional immunofluorescence 
microscopy (Figure 4.3). The detected antibody distribution by immunofluorescence 
microscopy indicated that defined cell populations and structures were labeled by this 
method. 
 
Figure 4.3: Antibody in vivo staining. Antibodies were injected i.v. 2.5 h (CD4, CD11c) or 0.5 h (MAdCAM-1) 
before perfusion. Specific antibody distribution was confirmed by conventional immunofluorescence microscopy. 
PP of (A) an untreated mouse and (B) of a mouse intravenously injected with fluorescent-labeled antibodies 
(MAdCAM-1 (green), CD11c (red) and CD4 (blue). Spleen of (C) an untreated mouse (w/o antibody) and (D) a 
mouse injected with antibodies. Sections were stained with DAPI ex situ (Scale bar: 100 µm).  
To further demonstrate that all the cells and target molecules in the tissues are stained 
specifically and none of the cellular events were missed with this particular staining protocol, 
we compared i.v. staining followed by traditional post-sectioning staining. Again we injected 
antibody i.v. (CD4 and MAdCAM-1) in an untreated BALB/c mouse 2.5 h or 30 min before it 
was euthanized. For post-section staining we used the same antibodies respectively, either 
CD4 or MAdCAM-1 labeled with a different fluorochrome than the antibody we had injected 
intravenously. All post-section staining were negative, indicating that the antibodies had 
efficiently entered the tissues (Figure 4.4A,B) and labeled CD4 or MAdCAM-1 proteins 
specifically. Furthermore, to demonstrate antibody distribution and specificity of inflamed 
tissues, CD4-Alexa647 antibody was injected in untreated mice or in mice at day+6 after 
allogeneic HCT. 2.5 h after antibody injection organs were digested in the presence of CD4-
FITC to prevent an ex post staining of remaining unbound CD4-Alexa647. Less than 2% 
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CD4-FITC single positive cells could be identified demonstrating an effective i.v. staining also 
under inflammatory conditions (Figure 3.4D). 
 
Figure 4.4: Distribution and specificity of i.v. antibody labeling procedure. To confirm antibody i.v. staining 
in an untreated BALB/c mouse (A) CD4 (red) was injected 2.5 h and (B) MAdCAM-1 (red) was injected 0.5 h 
before perfusion and post-section staining was performed with DAPI and respectively either with CD4 (green) or 
MAdCAM-1 (green) (20x, scale bar: 100 µm). Sections from mice injected with antibody (ab i.v.) were compared 
to sections from mice that did not receive antibody injection (w/o antibody). (C) Tiling of a whole PP cross-section 
with surrounding mucosal tissue indicates a specific whole tissue distribution of i.v. injected CD4 (red) antibody 
(20x, stitched from 30 images, scale bar: 500 µm). (D) FACS confirmation of i.v. antibody staining in inflamed and 
untreated tissues. CD4Alexa647 antibody was injected in untreated mice or in mice at day+6 after allo-HCT 
(inflammation). 2.5 h after injection spleen and PPs were digested in presence of CD4FITC antibody and 
subsequently analyzed with FACS. Cell frequency within the gate demonstrate an i.v. staining efficiency of > 98% 
of cellular events.  
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4.1.3 Quantification of immune processes in entire organs in a murine GVHD model 
As LSFM proved valuable to map individual immune cells in murine and human tissues, we 
consequently applied this technique to investigate evolving immune processes by repeated 
sampling. Consequently, we employed a model of acute GVHD to study T cell interactions 
with HEVs in whole PPs after allo-HCT (Beilhack et al., 2008). We induced acute GVHD in 
myeloablative conditioned BALB/c mice by transplanting bone marrow cells from C57Bl/6 
(CD90.2+, CD45.2+) donors and luciferase transgenic C57Bl/6 CD45.1+ or CD90.1+ T cells. 
We followed the in vivo progression of GVHD on a macroscopic level by non-invasive 
bioluminescence imaging (BLI) that pinpointed organs of donor T cell infiltration (Figure 4.5).  
 
Figure 4.5: From whole body bioluminescence to single cell LSFM imaging. Bone marrow together with 
luciferase+ CD45.1+ transgenic T cells were transplanted into irradiated allogeneic recipients to induce acute 
GVHD. Organs (indicated by arrows) were removed at the transition from GVHD initiation phase to effector phase 
(day+3 and day+4 after allo-HCT) and at the effector phase (day+6) and stained ex situ for donor T cells. Until 
day+3 the transplanted T cells proliferated within secondary lymphoid organs and started to egress by day+4. 
Scale bar: BLI 1 cm, LSFM overview 500 µm and detail 100 µm.  
At the transition from GVHD initiation to effector phase (day+3 to day+4 as described by 
Beilhack et al., 2005) and at the first peak of the effector phase (day+6) we prepared PPs 
(Figure 4.5) and other tissues of recipients for subsequent whole organ microscopy. To 
identify donor T cells we injected anti-CD45.1 or anti-CD90.1 specific monoclonal antibodies 
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i.v. and stained for the adhesion molecule MAdCAM-1 ex vivo on the fixed tissue. 
Subsequently we mapped and quantified the expression of MAdCAM-1 in relation to T cell 
numbers within PPs in the course of GVHD (Figure 4.6). Whereas LSFM allows clearly 
identifying single cells from different T cell subsets, dense lymphocyte clustering challenged 
automated cell counting. As a solution we calculated absolute T cell numbers in whole PPs 
by using the mean value of the measured cell volume (see 4.1.3.1 Cell counting). The 3D 
reconstruction of small intestines in healthy mice revealed that the MAdCAM-1 expression 
averaged at approx. 6% of the entire PP and was predominantly restricted to HEVs (Figure 
4.6A). During the GVHD initiation phase (day+3-4) the overall MAdCAM-1 expression in PPs 
 
Figure 4.6: Visualizing and quantifying cellular changes after allo-HCT in 3D. Bone marrow together with 
CD90.1+ transgenic T cells were transplanted into irradiated allogeneic recipients to induce acute GVHD. CD90.1 
or CD4 antibody, respectively, was injected i.v. MAdCAM-1 was stained ex situ. (A) Representative PPs of 
untreated (upper line) and transplanted mice highlight differences in MAdCAM-1 expression and numbers of 
donor T cells. (B) After allo-HCT MAdCAM-1 is highly upregulated in the PPs, particularly in follicular areas. (C) 
Quantification of donor T cells in the entire PP demonstrate proliferation until day+4. By day+6 most donor T cells 
exit as confirmed by BLI. Shown is one representative experiment of two with 2-4 mice per time point.  
increased by more than 50% and was even higher during the effector phase on day+6 after 
allo-HCT. At this point we found a massive MAdCAM-1 upregulation in follicular B cell areas 
(Figure 4.6B). Donor T cell numbers in the entire PP increased between day+3 and day+4 
(Figure 3.6C), demonstrating active cell recruitment and proliferation. By day+6 most donor 
T cells disappeared from the PPs indicating migration to peripheral GVHD target organs as 
confirmed by immunofluorescence microscopy of PP cross-sections (see 4.1.3.2 Confirming 
cell quantification within Peyer’s patches after HCT). On day+3 and day+4 high numbers of 
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donor T cells also located to MAdCAM-1 positive follicular areas which mostly disappeared 
by day+6.  
4.1.3.1 Cell counting 
Although we could clearly identify single T cells (stained for CD4, CD90.1 or CD45.1), dense 
lymphocyte clustering within PPs impeded automated counting. To overcome this limitation 
we measured T cells at less dense areas to quantify the mean volume per cell from the 
rendered voxel data (Figure 4.7A-F). The most frequent cell size was measured at 200-
400µm3 and averaged at 435.6 µm3 ± 19.7 (n = 233). To confirm this measurement with a 
well-established method we used confocal microscopy and indeed detected similar values 
(most frequent cell size 200-400 µm3, mean 561.1 µm³ ± 33.4, n = 195), supporting the 
volumes measured by LSFM. The size measurements may not reflect in vivo conditions of a 
CD4+ T cell. However, we could use the mean volume of a cell to calculate absolute T cell 
numbers in whole PPs. Now, upon allo-HCT the volume of an alloreactive T cell can 
dramatically change during activation. In fact, we found a significant increase of mean T cell 
volume (826.9 µm3 ± 17.2, n = 816) at day+3 after allo-HCT, that did not significantly differ to 
T cell volumes on day+4 and day+6. To avoid inexact enumeration caused by changing 
volume of donor T cells due to cell activation, we calculated mean values for day+3, day+4 
and day+6 after allo-HCT, respectively (Figure 4.7G-J).  
To further evaluate the approach of T cell number quantification via volume measurement, 
we compared three different ways to quantify absolute cell numbers by LSFM (Figure 4.8). 
First, we counted cells manually within a defined tissue volume and found 177 cells in total. 
Next, we counted 171 cells automatically within the same tissue via a Volocity software 
based computer algorithm described in the Methods section. Lastly, we quantified cell 
numbers by cell volume based calculation within the same tissue area and calculated 189 
cells.  
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Figure 4.7: Quantification of T cells in intact PPs.
(A) Clustering of T cells within a PP (CD4, red) impede automated cell counting (z-Projection; scale bar: 50 µm). 
(B) To calculate cell volumes, single CD4+ cells are rendered (colored objects) and measured at less dense 
areas. (C) Comparison of cell imaging with confocal microscopy and LSFM measurements (z-Projection; scale 
bar: 50 µm). Representative single cells imaged with (D) LSFM and (E) confocal microscopy using a 20x objective 
(z-Projection; scale bar: 10 µm). (F) Size distribution of measured CD4+ cells shown for LSFM (grey bars; mean 
volume 435.6 µm³ ± 19.7, n = 233) and confocal microscopy (white bars; mean volume 561.1 µm³ ± 33.4, n = 
195). (G) Donor T cells on day+3, (H) day+4 (I) and day+6 after HCT (z-Projections; scale bar: 50 µm). (J) Mean 
T cell volume was increased during activation (day+3 mean volume 826.9 µm3 ± 17.2 n = 816; day+4 mean 
volume 830.2 µm3 ± 27.9 n = 301, day+6 mean volume 788.8 µm3 ± 15.2 n = 976). Statistics: ANOVA, Bonferroni 
corrected (ns = P>0.05, *** = P<0.001). 
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Figure 4.8: Comparison of T cell number quantification via volume measurement with manual or 
automated cell counting procedures. (A) Using LSFM we imaged several non-clustering donor T cells (red, 
CD45.1+) infiltrating the intestinal mucosa at day+4 after allo-HCT (20x objective, increment: 3 µm, z-Projection 
from 150 sections, Scale bar: 100µm). (B) Colored objects indicate cells after automatic counting based on a 
software algorithm (Volocity) described in the Methods section. Volume calculations and automated cell counting. 
Z-Projection (upper image) and 3D rendered image (below). (C) Cyan indicates volume rendered objects. Z-
Projection (upper image) and 3D rendered image (below). (D) Comparison of T cell numbers counted manually, 
automatically with Volocity software or quantified by volumetric calculation based on the mean value of day+4 T 
cell volumes (830 µm3) to assess absolute T cell numbers within tissues.  
4.1.3.2 Confirming cell quantification within Peyer’s patches after allo-HCT 
In order to validate cellular quantification demonstrated by LSFM with another already 
established method we analyzed PPs after allo-HCT with flow cytometry. We transplanted 5 x 
106 bone marrow cells together with 2 x 106 B6.L2G85.CD90.1 T cells into irradiated BALB/c 
to induce acute GVHD and analyzed PPs at day+3, day+4, and day+6. Although flow 
cytometry is perfectly suited to analyze the relative cellular distribution within various organs, 
for the purpose of analyzing absolute T cell numbers in PPs, two major limitations had to be 
accounted for. First, in contrast to lymph nodes the excision of PPs is inaccurate and the 
surrounding mucosal tissue is biasing the FACS analysis. This issue becomes critically 
important when many donor T cells have entered the intestinal mucosa as it occurred on 
day+6 after allo-HCT (compare Figure 4.5, day+6, ex vivo BLI and LSFM overview). Second, 
the massive loss of cells during the preparation of the single cell suspension from PPs 
(cutting, digestion, cell strainer, washing steps, etc) impedes the calculation of exact cell 
numbers. To circumvent a bias caused by mucosal T cell infiltration we analyzed donor T cell 
numbers from equivalent pieces (in number and size) of PPs and small bowel samples and 
subtracted the detected cell numbers as displayed in Figure 4.9. However, for the given 
reason we doubt that the cell numbers of PPs after allo-HCT determined by flow cytometry 
reflect the correct cell numbers. 
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Figure 4.9: Flow cytometry analysis of PPs.
Bone marrow cells together with CD90.1+ 
transgenic T cells were transplanted into irradiated 
allogeneic recipients to induce acute GVHD. At 
day+3, day+4 and day+6 PPs and equivalent 
pieces (5-6 PPs/mouse) of small bowel (sb) were 
excised and digested (2 mg/ml collagenase D and 
0.1 mg/ml DNaseI, at 37°C for 30 min) for FACS 
analysis. Cells were suspended in equal volumes 
and stained for CD90.1 and CD45.2 to identify 
donor T cells. Dead cells were excluded by PI 
staining. Shown is one representative experiment of 
two with 4 mice per time point.  
Hence, we further validated the LSFM data by two alternative established approaches, 
namely BLI and IFM. We quantified the BLI signal of luciferase+ donor cells projecting to PPs 
(Figure 4.10A,B). Importantly, again we subtracted background signal (measured in small 
bowel areas without PPs) enhanced by small bowel infiltrating T cells and obtained 
comparable results to quantification with LSFM. Additionally we quantified donor T cells from 
a whole PP cross-section and again found similar changes in cell numbers within PPs 
(Figure 4.10C,D). Taken together, both semi-quantitative methods underpin our cellular 
LSFM results (specifically the rapid decline of donor cells between day+4 and day+6 after 
allo-HCT).  
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Figure 4.10: Visualizing and quantifying cellular changes within Peyer’s patches after allo-HCT. Bone 
marrow together with CD90.1+ luciferase+ transgenic T cells were transplanted into irradiated allogeneic recipients 
to induce acute GVHD. (A) Ex vivo BLI was performed at the transition from GVHD initiation phase to effector 
phase (day+3 and day+4 after allo-HCT) and at the effector phase (day+6). (B) Emitted photons of donor T cells 
in PPs (red circles) or intestinal mucosa (Sb, white circles) were quantified respectively. (C) PPs from day+3, 
day+4 and day+6 were stained for donor T cells with CD90.1 (red) and DAPI (blue) and whole PP sections were 
imaged in high-resolution with IFM (20x) and stitched together. Donor T cells were automatically counted with the 
Software Volocity (colored objects) by determining nuclei with a high MFI in the red channel, indicating cellular 
staining. (D) Quantification of whole PP sections. (scale bar: 500 µm). 
 
4.1.3.3 Imaging donor T cells  
We analyzed the suitability of fluorescent proteins for the detection of donor T cells with 
LSFM. Therefore, either we transplanted 4 x 106 B6.L2G85.DsRed splenocytes together with 
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5 x 106 C57Bl/6 bone marrow cells into BALB/c recipients. Using in vivo BLI we followed the 
T cell proliferation until day+3, day+4 or day+6 and we prepared PPs of recipients for LSFM. 
Although donor T cells could be detected with BLI ex vivo, after fixation and clearing of the 
sample we could not detect any DsRed+ signal neither with LSFM, nor with confocal and 
MPM (Data not shown). However, in tissue sections that were not fixed and cleared, we 
detected DsRed+ donor cells using IFM (Figure 4.11A). This observation indicates a loss of 
fluorescent protein signal due to the sample preparation for LSFM (fixation and clearing). To 
rule out whether PFA fixation affects the fluorescent proteins, we analyzed single DsRed+ 
cells with FACS (Figure 4.11B). Untreated DsRed+ spleen cells were easily detectable with 
FACS (MFI: 441), already 1 h after PFA fixation the cells had a 4 fold decreased MFI (MFI: 
129). After 7d the MFI of DsRed+ cells (MFI: 18.9) was comparable low to wt cells (MFI: 3.5). 
Hence, we found that PFA exposure can dramatically affect the brightness of DsRed+ cells 
even before tissue dehydration or BABB treatment maybe further affect the brightness of the 
fluorescent protein. 
Figure 4.11: PFA treatment affects 
fluorescent proteins. (A) DsRed+ donor 
T cells were detectable in tissue 
samples of allogeneic recipients with 
IFM, but could not be detected in 
samples that were fixed and cleared for 
LSFM (not shown). (B) To evaluate the 
influence of PFA fixation to fluorescent 
proteins, we treated DsRed+ and 
C57Bl/6 cells with PFA before analyzing 
the MFI with FACS.  
 
Since in our hands the sample preparation for LSFM impeded the successful detection of 
DsRed or GFP marked T cells, we used congenic markers (CD45.1 or CD90.1) to label 
donor T cells. Although the CD90.1 staining as congenic marker was sufficient for detection 
and counting of donor T cells, the display of the cells suffered from inhomogeneous labeling 
(Figure 4.12). Most cells displayed spots with 2-3 agglomerates of antibody, giving a much 
higher signal than the surface staining by itself. This was observed for the commercial 
available clones OX-7 and HIS51 and suggested clustering of the CD90 surface protein in 
the T cell membrane. In comparison when we stained for CD4 we achieved a homogenous 
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surface staining without any antibody agglomerations. This phenomenon was not only 
observed when we imaged intact tissues with LSFM but as well with conventional 
fluorescence microscopy imaging of stained cells that were placed on microscope slides 
(Figure 4.12). To guarantee an accurate visualization of the donor T cells we stained for 
CD45.1 and found that this antibody also resulted in a homogenous cell surface staining. 
While CD90 is expressed on T cells only, CD45 is expressed on all hematopoietic cells but 
mature erythrocytes and platelets and can also be used as congenic marker. Hence, we 
decided to utilize T cells from donor CD45.1+ mice for all subsequent experiments. 
 
Figure 4.12: Assessment of donor T cell staining with congenic markers. (A) CD4 staining of intact tissues, 
as well as single cell suspensions resulted in a uniform membrane staining of CD4+ cells. (B) When tissues of 
CD90.1+ T cells recipients were stained for CD90.1, donor cells appeared heterogeneously labeled. Most T cells 
displayed one to three intense fluorescent surface clusters, resulting in a decreased image quality. These surface 
antibody agglomerations were also detectable in stained single cell suspensions. (C) Contrary, tissues of CD45.2+ 
recipients stained for CD45.1 revealed uniformly labeled T cells. Scale bar: LSFM: 100 μm. 
4.1.4 Visualizing and counting rare events with LSFM 
As we were able to reliably visualize and quantify high numbers of donor T cells in PPs after 
HCT we tested whether multicolor LSFM is also capable of detecting rare cellular events. To 
this end we adoptively transferred FACS sorted CD4+ T cell subsets (CD62LhiCD44lo naïve TN 
cells, CD62LhiCD44hi central memory TCM cells and CD62LloCD44hi effector memory TEM 
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cells) as defined by Sallusto et al. (1999) from CD45.1+ donors (Figure 4.13A). Whole PPs 
and mLNs of the recipients were analyzed 20 h after T cell transfer. Using the software 
Volocity we established an algorithm (see section 2.2.15 Volume calculations and automated 
cell counting) that enabled us to automatically identify and count individual cells and found 
that TN cells (mean 726 cells/PP) homed more efficiently than TCM cells (mean 478 cells/PP) 
to PPs (Figure 4.13B,C) and to mLNs (Figure 4.14). Within the same experiment a similar 
homing trend to SLOs was confirmed by FACS analysis of the spleen (data not shown). TEM 
cells are preferentially localized in non lymphoid tissues instead of SLOs (Masopust et al., 
2001). In line with this, LSFM revealed low numbers of TEM (mean = 81/PP) homing to PPs 
(Figure 4.13B,C). Most TEM cells located in proximity to MAdCAM-1 expressing HEVs, 
indicating homing to the T cell zone.  
 
Figure 4.13: Detection of T cell homing by multicolor LSFM. (A) MACS-enriched CD4+ T cells (C57Bl/6-
L2G85 CD45.1+) were sorted into TN (CD44hiCD62Llo) TCM (CD44hiCD62Lhi) and TEM (CD44loCD62Lhi) and 
adoptively transferred into C57Bl/6 CD45.2+ recipients. (B) LSFM imaging of whole PPs allowed the detection of 
donor T cells 20 h after transfer. Left panel: 3D reconstruction of PPs autofluorescence (grey) and isosurface of T 
cells included in the automated quantification. Central Panel: 3D reconstruction of MAdCAM-1+ HEV (cyan) and 
isosurface of counted T cells (red). Right panel: representative section of the T cell area (20x, z-Projection, scale 
bar: 50 µm). (C) Quantification of transferred T cell numbers in the PPs (n = 3/group) revealed a better homing 
capacity of TN and TCM over TEM. In contrast TEM homed more efficiently to the liver (not shown). Antibody staining 
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was performed ex situ.  
 
 
Figure 4.14: Homing capacity of individual T cell subsets to mesenteric lymph nodes. LSFM imaging of 
whole mLNs allowed the detection of donor T cell subsets 20 h after transfer. According to the homing capacity to 
PPs, T cell numbers in the mLNs revealed a better homing capacity of (A) TN and (B) TCM over (C) TEM (z–
Projections, scale bar: 500µm).  
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4.2 Relevance of tissue alloantigen expression for selective GVHD 
organ manifestation 
4.2.1 Alloantigen tissue expression determines organ infiltration of TCR transgenic 
CD8+ T cells after allo-HCT 
To overcome the limitation of MHC- and miHAg-mismatched transplant models of GVHD that 
face the difficulty in determining the specific alloantigen that the responding T cells 
recognize, we employed TCR-transgenic T cells. The specificity of the TCR-transgenic T cells 
is restricted to a single peptide epitope that is either constitutively expressed in all organs or 
only in selected organs of the recipient. By employing such a model system we aimed to 
establish a model of allo-HCT that would be defined by a single antigen-mismatch 
recognized by donor T cells. 
To this end, we used TCR transgenic CD8+ T cells reactive with the OVA peptide SIINFEKL in 
the context of MHC class I H-2Kb (OT-I T cells) (Hogquist et al., 1994), to study antigen 
dependent T cell allo-responses after HCT ( 
Figure  4.15). Consequently we transplanted 2 x 106 splenocytes from B6.L2G85.OT-
I.Ragko.CD90.1 (CD8+ cell purity: > 80%) together with 5 x 106 BM cells from C57BL/6 into 
myloablative irradiated recipients (9 Gy) that matched in age and sex. The recipients 
expressed the cognate antigen either in all organs (βa-Ova), selectively in the pancreas 
(RIP-mOva), an organ that is normally unaffected by GVHD, or did not express ovalbumin at 
all (B6). We assessed weight change, and performed in vivo  
 
Figure 4.15: Scheme of T cell 
transplantation in a defined single 
antigen mismatch model. TCR-
transgenic B6.L2G85.OT-1.CD45.1 T 
cells together with bone marrow of a 
C57Bl/6 were injected into lethal 
irradiated B6a.βa-Ova, B6a.ins.ova or 
B6a recipients. Trafficking of 
alloreactive T cells in vivo was 
performed using BLI and at selected 
time-points by ex vivo BLI, flow 
cytometry, immunofluorescence 
microscopy or LSFM to analyze T cell 
migration at higher resolution. 
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BLI to analyze T cell proliferation and migration after allo-HCT. Until day+3 all OT-I T cell 
recipients as well as BM control and irradiation control lost about 10% of their initial body 
 
Figure 4.16: TCR transgenic CD8+ T cell migration after HCT is influenced by single alloantigen 
expression in the tissue. 
 (A) Body weight change after allo-HCT of 2 x 106 luciferase+ OT-I T cells together with 5 x 106 BM cells from a 
C57BL/6 donor into βa-Ova, RIP-mOva or B6 recipients. (B,C) In vivo BLI of recipients allowed a general 
assessment of T cell proliferation. (D) At day+6 after allo-HCT ex vivo BLI is pinpointing to specific T cell 
distribution (pancreas is indicated by an arrow) and (E) quantification of organ infiltration. (F) Serum levels of IL-6, 
IL-10, MCP-1, TNF, IL12p70 and IFN-y at day+6 after allo-HCT (ND indicates not detected).  
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weight (Figure 4.16A). While βa-Ova recipients lost up to 20% of weight until day+6 after 
HCT all other recipients regained weight. Unfortunately, the black fur of the recipient mice 
hindered the in vivo detection of photons from donor OT-I T cells and thus allowed only a 
general assessment of total flux. Allo-HCT of OT-I T cells into βa-Ova recipients resulted in a 
strong acceleration of photon emission starting at day+1 after HCT indicating a high T cell 
responsiveness followed by proliferation (Figure 4.16B). In comparison to B6 recipients RIP-
mOva mice showed a slight signal increase starting at day+3 after HCT. At day+6 after HCT 
in βa-Ova donor T cell distribution apparently span the whole body while in RIP-mOVA mice 
the BLI signal seemed to project to the thymus but no further reliable information on specific 
organ infiltration could be gathered. Hence, we euthanized the recipients and performed ex 
vivo BLI to further evaluate organ infiltration by donor T cells at day+6 after HCT. The 
imaging of the resected organs (cLNs, thymus, heart, lung, kidneys, iLNs, liver, spleen, 
pancreas, and gastrointestinal tract) provided higher resolution of selective signal distribution 
and revealed an overall organ infiltration of OT-I T cells in βa-Ova recipients (Figure 4.16D). 
In RIP-mOva mice we found photon emission by donor T cells in the spleen, the mLNs, to 
some extend in the small bowel and mainly in the thymus and the pancreas. In B6 recipients 
that do not express ovalbumin at all, BLI revealed OT-I T cells only in the spleen and partially 
in the small bowel (here probably within PPs). Measurements of the mean flux (photon 
emission/ second/ cm2) per organ confirmed an overall organ infiltration of OT-I T cells within 
βa-Ova recipients (Figure 4.16E). All organs of βa-Ova mice showed higher OT-I cell 
infiltration than organs of RIP-mOva or B6 recipients. We found especially high mean flux 
values per organ in SLOs (spleen, cLN, iLN, and mLN), thymus, lung, and pancreas that 
exceeded 1 x 105 photons/sec/cm2. Compared to B6 recipients RIP-mOva mice showed a 
significant higher OT-I cell infiltration only in the thymus, lung, and pancreas whereas in liver, 
small bowel, spleen, and mLNs only little higher flux was detectable. 
After BLI the resected organs were either snap frozen or stored in 4% PFA for 
histopathological analysis. Immunhistochemistry staining of CD90.1 revealed donor OT-I T 
cells distribution in diverse organs of different recipients (Figure 4.17). While donor OT-I T 
cells scattered throughout the whole spleen of βa-Ova recipients, in RIP-mOva and B6 
recipients they mainly adhered to the red pulp (Figure 4.17A, spleen). The pancreas of βa-
Ova recipients was heavily infiltrated by OT-I T cells while no OT-I T cells were found in B6 
recipients. Remarkably, in pancreas of RIP-mOva recipients OT-I donor T cell infiltration was 
almost exclusively restricted to the islets (Figure 4.17A,B). Similar to other organs the large 
bowel and liver of βa-Ova recipients were severely infiltrated by OT-I T cells. In comparison, 
only few OT-I T cells could be identified in the large bowel but not in the liver of RIP-mOva 
recipients and no OT-I T cells were detectable in B6 recipients. The histopathological GVHD 
scoring of typical GVHD target-tissues from βa-Ova revealed grade 2 GVHD in the large 
RESULTS 
61 
 
bowel, grade 1 GVHD in the liver, while no symptoms of GVHD was detectable in the skin by 
day+6 after HCT (Figure 4.17C). No signs of GVHD were detectable in GIT, liver or skin of 
RIP-mOva and B6 recipients. 
 
Figure 4.17: Histopathological analysis of CD90.1+ donor OT-I cell infiltration of different recipient tissues. 
(A) At day+6 after single antigen mismatch allo-HCT of 2 x 106 OT-I T cells, recipients tissues, such as spleen 
large bowel (Lb), liver, and pancreas were investigated after immunhistochemistry staining. Pancreatic islets, 
indicated with arrows, (B) are shown with higher magnification. (C) GVHD scoring at day+6 after allo-HCT was 
performed by an experienced pathologist (Stephan Schulz). 
We repeated the experiment with the same conditions, by using male donors and recipients. 
The results of this experiment are shown in Figure 4.18 and confirmed previous findings. 
Since more mice per group were available (n ≥ 8 mice/group) we additionally assessed 
survival of remaining mice after sacrificing 3 mice/group for ex vivo BLI at day+6 after HCT. 
Until day+3 all OT-I T cell recipients as well as BM control and irradiation control lost about 
10% of their initial body weight (Figure 4.18A). While βa-Ova recipients lost up to 20% of 
weight until day+6 after HCT all other recipients regained weight. Again, initially all mice lost 
body weight until day+3, while βa-Ova recipients lost weight until day+6 after HCT. At day+6 
βa-Ova recipients crouched with a hunchback and displayed clinical GVHD symptoms after 
OT-I T cell transplantation. Surprisingly, shortly thereafter those mice regained rapidly weight 
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and by day+14 after HCT reached more than 110% of their initial body weight. Bone marrow 
control mice as well as B6 recipients of OT-I T cells regained weight already after day+3 and 
weighed more than 100% at day+25 after HCT. In contrast, RIP-mOva recipients started 
again losing weight at day+6 after HCT. Two of three RIP-mOva mice died at day+8 and the 
last mouse died 14 days after HCT.  
 
Figure 4.18: Cognate antigen expressing tissue is infiltrated by OT-I T cells after single antigen mismatch
HCT. (A) Body weight change of different recipients after allo-HCT of OT-I T cells. (B) Immunhistochemistry 
staining of CD90.1+ OT-I T cells in kidney, large bowel (Lb) and pancreatic tissue of βa-Ova and RIP-mOva 
recipients at day+6 after allo-HCT. Arrows indicating pancreatic islets (Scale: 100 µm). (C) CD90.1+ OT-I T cells 
were counted in 10 representative high power fields (HPFs) of kidney, large bowel (Lb), small bowel (Sb) and 
pancreas and mean values ± standard deviations are listed.  
Immunohistochemistry staining revealed CD90.1+ donor OT-I T cells in selected tissues of 
different recipients. We counted donor T cells per 10 high power fields (HPFs) and found 
similar numbers in different organs of βa-Ova recipients, ranging from 244 ± 48.7 (Mean ± 
SD) OT-I T cells within the pancreas to 332.7 ± 39.8 (mean ± SD/ HPF) OT-I T cells in the 
large bowel. In contrast, RIP-mOva mice had only very few OT-I T cells in the kidney 3.3 ± 
3.0 (mean ± SD / HPF) some more OT-I T cells were found in the large bowel (29.7 ± 9.3, 
mean ± SD / HPF) and many OT-I T cells could be detected in the pancreas (120.3 ± 69.7, 
mean ± SD / HPF). Although BLI signal intensity of large bowel and small bowel of RIP-mOva 
and B6 recipients were comparable, little less OT-I T cells were found in B6 recipients using 
immunohistochemistry. However, no OT-I T cells were found in kidney or pancreas of B6 
recipients. 
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4.2.2 Effective T cell mediated destruction of single alloantigen expressing target 
tissues  
In contrast to previous studies that reported about insufficiency of single antigen disparity to 
cause GVHD (Fontaine et al., 2001) Toubai et al. (2012) found that a single H-Y antigen 
disparity can cause GVHD, when transferring sufficient numbers of alloreactive precursor 
cells. In our experiments we found donor T cells effectively infiltrating alloantigen expressing 
tissues on day+6 after allo-HCT. This implies that the transferred number of T cells was 
sufficient to evoke an alloantigen response, including effective T cell priming, proliferation 
and migration to the alloantigen expressing tissues. 
To test whether the specific infiltration of alloantigen expressing tissues is dependent on high 
numbers of alloreactive precursor cells, we next decreased the numbers of transferred T 
cells. Therefore, we FACS sorted OT-I CD45.1+luciferase+ cells (CD8+ post sort purity: 
99.5%) and transplanted either 1 x 106, 1 x 105, 1 x 104 or 1 x 103 T cells together with 5 x 106 
C57Bl/6 bone marrow cells either into irradiated βa-Ova (n = 4 mice/group) or RIP-mOva (n = 
5 mice/group). As syngeneic control we transplanted 1 x 105 OT-I T cells together with 5 x 
106 C57Bl/6 bone marrow cells into C57Bl/6 recipients. We analyzed luciferase+ T cell 
proliferation using BLI, measured blood glucose and assessed weight change and survival. 
We imaged RIP-mOva with BLI on day+6 after allo-HCT and detected T cell proliferation in 
mice receiving 1 x 106 or 1 x 105 OT-I T cells and to lesser extent in recipients of fewer OT-I T 
cells (Figure 4.19A). We stopped imaging at this time since several RIP-mOva recipients 
already showed first signs of sickness (ruffled fur, weight loss). Almost all recipients of 1 x 106 
and 1 x 105 OT-I T cells had high blood glucose levels at day+8, indicating a dramatic 
destruction of islets by OT-I T cells by this time, and died within 15 days after allo-HCT. Blood 
glucose levels of 1 x 104 OT-I T cells recipients were high at day+10 and at day+12 recipients 
of 1 x 103 OT-I T cells had high glucose levels (Figure 4.19B). All mice died within 24 days 
after allo-HCT (Figure 4.19C,D). These results suggested that alloantigen recognition, as well 
as the specific alloantigen expressing tissue infiltration by CD8+ T cells after allo-HCT was 
very efficient as 1 x 104 OT-I T cells were enough to cause severe islet destruction. 
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Figure 4.19: Effective T cell mediated destruction of cognate antigen expressing target tissues after 
single antigen mismatch allo-HCT of OT-I T cells into RIP-mOva recipients. (A) BLI at day+6 after allo-HCT 
of different cell numbers of luciferase+ OT-I T cells together with 5 x 106 BM cells from a B6 donor into B6a.RIP-
mOva or B6a recipients. Administered OT-I cell numbers are indicated (e.g. 106 or e6 indicates recipients of 1 x 
106 OT-I T cells). (B) Blood glucose measurement is indicating critical time points of islet destruction (each dot 
represents an analyzed recipient and mice with levels above 300 mg/dl were considered diabetic). (C) Weight 
change and (D) Kaplan-Meier survival curves after allo-HCT of decreasing OT-I cell numbers.  
In contrast, the survival of βa-Ova recipients was dependent on transplanted OT-I cell 
numbers (cell number / survival: 1 x 106 / 25%; 1 x 105 or 1 x 104 / 75% and 1 x 103 / 100%). 
Using BLI we detected a strong proliferation of luciferase+ T cells in recipients of 1 x 106 and 
1 x 105 OT-I T cells between day+3 and day+6 (Figure 4.20A,B). No βa-Ova recipient died 
after day+15 (Figure 4.20D,C) and none of the βa-Ova recipient had high blood glucose 
levels (data not shown). 
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Figure 4.20: Survival of βa-Ova recipients is dependent on OT-I cell numbers of allo-HCT. (A) BLI and (B) 
quantification after allo-HCT of different luciferase+ OT-I cell numbers together with 5 x 106 BM cells from a B6 
donor into B6a.βa-Ova or B6a recipients. Administered OT-I cell numbers are indicated (e.g. 106 or e6 indicates 
recipients of 1 x 106 OT-I T cells). (C) Weight change and (D) survival was assessed until day+60 after allo-HCT 
of decreasing OT-I cell numbers.  
4.2.3 Quantification of organ infiltrating OT-I T cells with flow cytometry 
We analyzed tissues of different recipients with flow cytometry to determine infiltrating OT-I 
cell-numbers at defined time points.  
For single antigen mismatch allo-HCT we transferred 1.2 x 106 OT-I CD45.1+ cells (CD8+ 
purity: approx. 80%) together with 5 x 106 C57Bl/6 bone marrow cells into irradiated B6a.βa-
Ova, B6a.RIP-mOva or B6a recipients (n = 6 mice/group). At day+4 and at day+6 mice were 
euthanized and we collected spleen, kidney, pancreas, lung, liver, small bowel (sb), and large 
bowel (lb). Importantly, all organs were collected in regard of comparable sizes to achieve 
comparable volumetric enumeration (left kidney and left lung, whole spleen and pancreas 
excluding pancreatic LNs by visual encounter), one representative lobe of the liver, exactly 
4 cm of sb or lb without PPs). For cell dissociation, but for the spleen all organs were cut in 
small pieces followed by enzymatic digestion. Cells were suspended and analyzed in defined 
volumes to calculate donor OT-I cell numbers. We identified donor T cells by CD45.1+ and 
CD8+ staining as indicated in Figure 4.21.  
RESULTS 
66 
 
 
Figure 4.21: Enumeration of organ infiltrating OT-I T cells using FACS. Conditioned recipients of βa-Ova, 
RIP-mOva or B6 were injected with MACS enriched 1.2 x 106 CD45.1+ OT-I T cells together with 5 x 106 BM 
cells from a C57BL/6 donor. At day+4 and day+6 after allo-HCT, tissues were removed and cell suspensions 
were prepared for flow cytometry. (A) Representative FACS plots and gating on CD45.1+ OT-I T cells, isolated 
from recipients. (B) Quantification of OT-I donor cells (n = 3 mice/group).  
In βa-Ova mice we identified at day+4 large numbers of OT-I T cells in spleen, kidney, 
(Figure 4.21) liver, and lung. In these recipients OT-I cell numbers in spleen and liver 
decreased between day+4 and day+6, but increased in all other investigated organs. In RIP-
mOva and B6 recipients we could only identify large numbers of OT-I T cells in the spleen 4 
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days after allo-HCT (Figure 4.21A). Until day+6 we detected a slight increase of OT-I T cells 
in tissues of B6 recipients, except within the pancreas (Figure 4.21B). Here we found 
decreasing cell numbers, which might be explained by blood circulating OT-I T cells on 
day+4. Similarly, we detected a slight increase of OT-I T cells in tissues of RIP-mOva 
recipients and slightly decreasing OT-I cell number in the small bowel. However, in these 
recipients pancreas infiltration by OT-I T cells increased by more than 100 fold between 
day+4 and day+6, strongly indicating a specific accumulation of donor OT-I T cells. 
4.2.4 Identification of organ infiltrating OT-I T cells with LSFM  
As described above (Chapter 4.1) we have demonstrated that LSFM is a reliable method to 
visualize and quantify high numbers of donor T cells after HCT as well as detecting rare 
cellular events within various adult mouse organs. Consequently, we employed this 
technique to study the kinetic of alloantigen dependent tissue infiltration by alloreactive T 
cells. 
To guarantee the detection of T cells infiltrating the pancreatic islets, we first established the 
imaging of large areas deep within the intact pancreas. The clearing of pancreatic tissue 
resulted in optically transparent samples. Subsequently, to effectively detect first donor T 
cells infiltrating islets of ovalbumin expressing beta cells we established an anti-insulin 
antibody staining to visualize insulin producing islets in the pancreas (Figure 4.22A). Islets 
itself were already identifiable due to a higher autofluorescence in the green channel 
compared to the surrounding pancreatic tissue. Again, in an allo-HCT we transferred 1.2 x 
106 OT-I CD45.1+ cells (CD8+ purity: approx. 80%) together with 5 x 106 C57Bl/6 bone 
marrow cells into irradiated B6a.RIP-mOva recipients. At indicated time points we perfused 
mice with PFA and prepared organs for LSFM imaging. By scanning large tissue volumes we 
detected first few pancreatic islets infiltrating OT-I T cells the earliest by day+4 after allo-HCT 
followed by a massive T cell migration to the pancreas within the following 24 h (Figure 22B-
D). In comparison we found only few cells in other peripheral organs, such as the liver or 
large bowel.  
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Figure 4.22: Identification of organ infiltrating OT-I T cells using LSFM. (A) Pancreatic tissue imaging: 
autofluorescence in the green channel already revealed pancreatic islets (indicated by an arrow). Staining of α-
insulin colocalized with the enhanced islet autofluorescence (scale upper panels 500 µm, lower panel 200 µm). 
(B) CD45.1+ OT-I cell infiltration in tissues of RIP-Ova recipients at indicated time points after single antigen 
mismatch allo-HCT (z-Projections, scale 500µm). (C) Detailed comparison of CD45.1+ OT-I cell in pancreatic 
tissue of βa-Ova and RIP-mOva mice at day+4 after allo-HCT (z-Projections, scale 200 µm). (D) 3D 
reconstruction of pancreatic island infiltration of RIP-Ova mice by CD45.1+ OT-I T cells at indicated time points 
after allo-HCT.  
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4.2.5 Antigen expression by either hematopoietic, or by parenchymal cells only 
result in alloreactive T cell organ infiltration  
Next, we asked whether the expression and presentation of cognate antigens on the 
hematopoietic or exclusively non-hematopoietic host cells would affect the tissue distribution 
of TCR transgenic CD8+ T cells after allo-HCT. 
Therefore, we generated B6  B6a (B6/B6) or βa-Ova  B6a (βa-Ova/B6) chimeras such 
that the ovalbumin antigen is encoded only by host hematopoietic cells and not by non-
hematopoietic target tissues. After three months the chimerism in the blood was 93.4% ± 
3.7% (n = 14). The chimeras were then used as allo-HCT recipients, injected with 5 x 106 
C57Bl/6 bone marrow cells plus 2 x 106 OT-I T cells (purity after MACS enrichment > 85% 
CD8+). Only dim bioluminescence signals were detectable in B6/B6 recipients and luciferase+ 
signal of OT-I T cells mainly projected to the SLOs at day+6, suggesting homeostatic 
proliferation (Figure 4.23A-C). In contrast, we found massive proliferation of OT-I T cells in 
βa-Ova/B6 recipients as indicated by BLI. At day+3, bioluminescence signals of OT-I T cells 
mainly projected to the liver and SLOs such as cLN, iLN, and spleen. Already 24 h later the 
cells left the liver and spread within the recipient. At day+6 after allo-HCT ex vivo BLI 
revealed a whole organ distribution of OT-I T cells in βa-Ova/B6 recipients (Figure 4.23D,E). 
At this time point we found increased levels of MCP-1 and IFN-γ in βa-Ova/B6 recipients 
(Figure 4.23F).  
Next we generated βa-Ova  βa-Ova (βa-Ova /βa-Ova) and B6  βa-Ova (B6/βa-Ova) 
chimeras such that the ovalbumin antigen is encoded only by non-hematopoietic target 
tissues and not by hematopoietic cells (B6/βa-Ova), or encoded by both (βa-Ova /βa-Ova). 
Again, we waited three months (chimerism > 95%) before chimeric mice were used as single 
antigen mismatch allo-HCT recipients, injected with 5 x 106 C57Bl/6 bone marrow cells plus 2 
x 106 OT-I T cells (purity after MACS enrichment > 78% CD8+). At day+6 after allo-HCT BLI 
revealed that all organs were infiltrated in a similar pattern with similar levels of OT-I cell 
proliferation and organ infiltration, irrespectively whether the antigen was expressed only by 
non-hematopoietic target tissues, only by hematopoietic cells, or expressed by both (Figure 
4.24).  
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Figure 4.23: Cognate antigen expression by hematopoietic cells results in an overall organ infiltration by 
alloreactive T cells. Chimeras were generated, so that ovalbumin is either expressed only on hematopoietic-
derived cells (βa-Ova/B6) or is not expressed at all (B6/B6). These chimeras were then irradiated and 
transplanted with 2 x 106 luciferase+ OT-I T cells together with 5 x 106 BM cells from a C57BL/6 donor. (A) Body 
weight change after allo-HCT was assessed until day+6. (B,C) In vivo BLI of recipients revealed OT-I cell 
proliferation and migration. (D) At day+6 after allo-HCT ex vivo BLI revealed T cell distribution and (E) 
quantification of organ infiltration. (F) Serum levels of IL-6, IL-10, MCP-1, TNF, IL12p70 and IFN-y at day+6 after 
all-HCT.  
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Figure 4.24: Cognate antigen expression solely by non-hematopoietic target tissues only results in an 
overall organ infiltration by alloreactive T cells. Chimeras were generated, so that ovalbumin is either 
expressed by non-hematopoietic target tissues and hematopoietic-derived cells (βa-Ova/βa-Ova), only by non-
hematopoietic target tissues (B6/βa-Ova), only on hematopoietic-derived cells (βa-Ova/B6),or is not expressed at 
all (B6/B6). These chimeras were then irradiated and transplanted with 2 x 106 luciferase+ OT-I T cells together 
with 5 x 106 BM cells from a C57BL/6 donor. (A) In vivo BLI and (B) ex vivo BLI at day+6 after allo-HCT revealed 
OT-I cell proliferation and migration. (C) Quantification of in vivo BLI and (D) ex vivo BLI demonstrated similar 
pattern of OT-I cell proliferation and organ infiltration in βa-Ova/βa-Ova, B6/βa-Ova and βa-Ova/B6 recipients and 
only homeostatic proliferation in B6/B6 recipients.  
4.2.6 OT-I proliferation ability and IFN-γ production in vitro 
As we had found high levels of IFN-γ in the serum of OT-I recipients that expressed 
ovalbumin (βa-Ova, βa- Ova-chimeras and RIP-mOva) we asked whether the IFN-γ 
production might be induced by donor T cells. Therefore, we analyzed the ability of OT-I cell 
proliferation as well as IFN-γ production upon antigen presentation in vitro. Therefore, we 
isolated OT-I T cells from spleens of donor mice and labeled them with CFSE. Naïve OT-I T 
cells were stimulated either with an alloantigen independent TCR stimulation by adding CD3+ 
antibody together with IL-2 or with irradiated splenocytes from βa-Ova mice (target cells). 
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After 3 days of stimulation, the effector OT-I T cells were either re-confronted with target cells 
or were not re-challenged. After 5 h of re-stimulation we analyzed IL-2 and IFN-γ production 
of OT-I T cells by intracellular staining and FACS. OT-I T cells showed great  
 
Figure 4.25: OT-I cell proliferation and IFN-γ production in vitro. CD45.1+ OT-I T cells 
were stimulated either with CD3+ antibody (CD3+) or with irradiated spleen cells from 
βa-Ova mice (target) and were subsequently either re-stimulated with βa-Ova cells or 
not exposed to an antigen again (rest). (A) Representative FACS plots and gating of 
CD45.1+ effector cells as well as intracellular staining of IL-2 and IFN-γ. Quantification 
of (B) IL-2+ and (C) IFN-γ+ OT-I T cells after stimulation and re-stimulation (n = 
6/treatment).  
proliferation capacity upon CD3+IL-2-stimulation or target cell stimulation as indicated by 
CFSE dilution (Figure 4.25A, first panel). OT-I T cells stimulated with target cells and re-
stimulated with target cells (target/target) showed some IL-2 production (Figure 4.25A,B 
mean: 1.1%, n = 5). In comparison, OT-I T cells stimulated with CD3+IL-2 and re-stimulated 
with target cells (CD3/target) showed much higher IL-2 production (CD3/target, mean: 
12.65%, n = 3). This high numbers of IL-2 producing OT-I T cells could not be found when 
CD3+IL-2 stimulated cells were not re-stimulated with target cells (CD3/resting mean: 0.0%, 
n = 5). We found a dramatic IFN-γ production of effector OT-I T cells when re-stimulating with 
target cells (target/target, mean: 45.6%, n = 5; CD3/target, mean: 42,2%, n = 3). We could 
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not observe IFN-γ production of effector OT-I T cells that were not re-stimulated after priming 
(CD3/resting, mean: n = 3).  
Hence, OT-I T cells showed great potential of proliferation upon alloantigen presentation in 
vitro, leading to dramatic IFN-γ and to a lesser extent to IL-2 production upon re-encounter 
with the cognate alloantigen. 
4.2.7 Cognate antigen recognition of TCR transgenic CD4+ T cells - proliferation and 
migration of OT-II cells  
To rule out whether alloantigen dependent tissue infiltration, as observed for CD8+ T cells at 
day+6 after OT-I allo-HCT, might also occur after allo-HCT of CD4+ T cells that depend on 
MHC II recognition, we employed TCR transgenic OT-II T cells in an allo-HCT setting. 
Consequently, we transplanted either 1 or 2 x 106 FACS sorted luciferase+ CD4+ T cells from 
B6.L2G85.OT-II.Ragko.CD45.1 donors (purity: > 98% CD4+) together with 5 x 106 BM cells 
from C57BL/6 mice into myeloablatively irradiated (9 Gy) B6a.βa-Ova or B6a.RIP-Ova 
recipients, that matched in age and sex. We used in vivo BLI to analyze T cell proliferation 
and migration after transplantation. 
In βa-Ova recipients of OT-II T cells, we found a strong acceleration of photon emission 
starting at day+2 after HCT indicating a high T cell responsiveness followed by proliferation 
(Figure 4.26A,B). At this time point BLI signal mainly projected to cervical LNs as well as 
spleen, suggesting an effective homing to and priming in SLOs. In vivo BLI indicated that by 
day+3 after HCT the first OT-II T cells migrated from SLOs to peripheral organs such as the 
GIT. In contrast, in RIP-mOva recipients that had received 1 x 106 (n = 3) OT-II T or 2 x 106 (n 
= 1) OT-II T cells, donor T cells were not detectable by day+6 after HCT using BLI (Figure 
4.26A). At day+6 after HCT we performed ex vivo BLI to evaluate organ infiltration by donor T 
cells in more detail. Ex vivo imaging of organs from βa-Ova recipients revealed an overall 
organ infiltration of OT-II cells, while no luciferase signal was detectable in RIP-mOva 
recipients (Figure 4.26C,D).  
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Figure 4.26: Cognate antigen recognition of TCR transgenic CD4+ T cells – proliferation and migration of 
OT-II cells. 
(A, B) 1 x 106 CD4+ FACS sorted luciferase+ OT-II cells together with 5 x 106 BM cells of a C57Bl/6 donor were 
injected into irradiated RIP-Ova and βa-Ova mice and T cell expansion and migration was analyzed with BLI. 
(C,D) At day+6 after allo-HCT ex vivo BLI revealed massive luciferase+ T cell distribution in all organs of βa-Ova 
recipients, but not in RIP-mOva. (E,F) BLI revealed that transplanted luciferase+ OT-II cells in RIP-mOva were 
partly located in the bone marrow compartments and slightly expanded until day+14 (ve, ventral; la, lateral; do, 
dorsal). 
Hence, we repeated single antigen mismatch allo-HCT of OT-II (post FACS purity 97.8% 
CD4+) into RIP-mOva recipients (n = 8). Again we could barely detect luciferase+ donor cells 
before day+6 after HCT. At day+6 focal spots, projecting to bone marrow compartments such 
as spine or femur, appeared and increased in signal intensity until day+14 after-HCT (Figure 
4.26E,F). However, when we examined the recipients until day+21 after single antigen 
mismatch allo-HCT we neither observed further OT-II donor cell proliferation nor any clinical 
signs of acute GVHD. 
  
 
5 Discussion 
5.1 Mapping immunological processes in intact organs using LSFM 
The vertebrate immune system exhibits an enormous complexity that requires the approach 
of employing new imaging technologies to study structural and functional processes in its 
biological context. Molecular 3D imaging techniques are very instrumental in revealing 
cellular events in tissues and organs (Ludewig et al., 2012). Another benefit of molecular 
imaging is that the images provide quantitative data, while preserving the intact structure of 
the experimental subject (Massoud and Gambhir, 2003). To this end, we established a novel 
convenient and versatile technique of optical light sheet illumination microscopy that allows 
visualizing and automatizing of single cell analysis within whole organs in multiple colors.  
5.1.1 A virtual journey through intact tissues by advanced multicolor LSFM 
A self-built prototype multicolor LSFM enabled us to investigate multiple tissues based on the 
principal of optical sectioning, a procedure of tissue clearing for optimal light penetration and 
computational 3D reconstruction. In my thesis project, we demonstrated for the first time that 
this technique is suitable to analyze complex immune processes in whole secondary 
lymphoid organs (e.g. PPs and mLNs) and showed its application to diverse murine and 
human tissues including lung, liver, heart, skin, and testicles. Importantly, we also established 
deep-tissue staining protocols for multicolor display of individual cell distribution, achieved 
subcellular sensitivity and quantified absolute cellular infiltrates by employing a single 
microscopy setup.  
Multicolor LSFM fills a gap between microscopic imaging techniques like confocal 
microscopy and macroscopic imaging techniques as magnetic resonance imaging (MRI) and 
computer tomography (CT), or bioluminescence imaging (in experimental models). Hereby, 
LSFM circumvents the obstacle of alternative 3D imaging methods such as optical projection 
tomography (OPT) that suffer from the requirement of time-consuming backprojection 
(Sharpe et al., 2002). A clear advantage of LSFM is that optical sectioning allows the rapid 
screening for rare events in mesoscopic specimens without requiring any image calculation. 
Therefore, areas of interest can be identified immediately during the acquisition process 
which allows for more focused investigation at higher magnifications.  
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5.1.2 Application of LSFM in multiple tissues of mice and human 
Labeling of intact tissues with multiple fluorescent antibodies for 3D imaging opens a broad 
range of biomedical applications. The utilization of antibodies is highly flexible because any 
molecule of interest can be stained, while fluorescent proteins are inapplicable for human 
tissues or wild type animal models. In cleared samples high tissue autofluorescence 
particularly in the green color channel, caused by formalin fixation (Leischner et al., 2010), 
allows the display of detailed microanatomical features in various organs. This proved 
advantageous to locate specific fluorescently labeled cell populations within their anatomical 
context. However, this strong autofluorescent background noise also poses certain limitations 
to utilize green fluorophores and therefore, we recommend reliance on fluorophores in the 
red or near-infrared color spectrum, as demonstrated in this study. Fluorescent proteins have 
been proven to be beneficial for many biological applications and were used for various 
imaging techniques in the past decade (e.g. Betzig et al., 2006; Hoffman and Yang, 2006). 
Especially the development of new available fluorescent proteins promises many innovative 
tools for biological imaging (Shaner et al., 2004, 2005). Thus, we also aimed to track donor T 
cells expressing fluorescent proteins with LSFM after HCT, but in our hands were not able to 
detect them after the clearing procedure. However, other groups demonstrated the suitability 
of fluorescent proteins in imaging motor neurons expressing DsRed-Express (Ermolayev et 
al., 2009a, 2009b) or neurons expressing GFP (Dodt et al., 2007), after the samples have 
been incubated with clearing solution. More recently, several protocols have been 
established to retain the stability of certain fluorescent proteins in restricted tissues by 
avoiding the use of clearing solution (Ertürk et al., 2011, 2012; Hama et al., 2011). 
To further improve LSFM we envision to implement several alterations that promise to further 
increase contrast, generate less image artifacts, and provide even higher resolution such as 
illumination from two sides (Dodt et al., 2007), scanning the light sheet (Huisken and Stainier, 
2007; Keller et al., 2008), structured-illumination (Keller et al., 2010), Bessel beam plane 
illumination (Planchon et al., 2011) or even combination of LSFM with STED microscopy 
(Friedrich et al., 2011). Recent improvements to optimize clearing procedures rendering 
organs transparent, as shown for the central nervous system (Ertürk et al., 2011; Hama et al., 
2011) will further assist to reduce background fluorescence and enhance fluorescent protein 
stability. 
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5.1.3 Quantification of immune processes in entire organs using a murine GVHD 
model 
After we established multicolor LSFM staining protocols and tissue analysis methods we 
applied this technique to monitor dynamic changes within PPs during acute GVHD. Here, 
especially the combination of BLI with LSFM proofed to be very effective for whole body T 
cell tracking in vivo to a detailed single cell imaging (ex situ). BLI is a well established 
method to effectively explore and evaluate complex immunological processes such as GVHD 
and GVL reactions (Edinger et al., 2003; Cao et al., 2004, 2005; Beilhack et al., 2005). 
Thereby the sensitivity of BLI is sufficient to detect 100–1.000 lymphoma cells (Edinger et al., 
2003) or even 10 T cells (Rabinovich et al., 2008) in vivo and the ability to serially track cell 
populations non-invasively allows for the identification of key time points and locations for 
further analysis (Negrin and Contag, 2006). Further optical imaging techniques, including 
fluorescence imaging, exist to generate whole-body images of HCT recipients (Panoskaltsis-
Mortari et al., 2004) and might be helpful in combination with LSFM. 
Imaging whole PPs of recipients that underwent HCT with LSFM we found a dramatic 
upregulation of MAdCAM-1 on HEVs and within follicular areas. It is well established that 
MAdCAM-1 is an important regulator in lymphocyte homing to PPs via HEVs (Hamann et al., 
1991) but is also expressed on marginal reticular cells and follicular dendritic cells (Szabo et 
al., 1997) and thus is thought to potentially contribute to lymphocyte motility (Boscacci et al., 
2010). In accordance with our findings, Szabo et al. (1997) found an enhanced MAdCAM-1 
expression within peripheral lymph nodes and spleen in response to antigenic stimulation. 
However, the exact function of this dynamic MAdCAM-1 regulation in follicular areas still 
needs to be further elucidated. Furthermore, in my thesisproject, we successfully quantified 
donor T cell numbers in the entire PPs. The dense clustering of the T cells impeded 
automated cell counting and we calculated cell numbers by using the mean value of the 
measured cell volume. Because of the limited number of fluorescent channels available we 
did not stain for the nuclei. Nuclear staining in combination with surface molecule staining 
may have facilitate automated cell count as demonstrated previously (Bolte and Cordelières, 
2006). However, with solely optical sectioning by LSFM, these quantifications were not prone 
to artifacts that occur on cut surfaces. This turned out to be particularly advantageous when 
reliable counting of rare cellular events is required and hundreds of serial cryo-sections may 
become overly challenging.  
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5.1.4 Visualizing and counting rare events with LSFM 
We investigated the fate of individual CD4+ T cell subsets that either induce (TN and TCM) or 
do not induce (TEM) lethal GVHD after allo-HCT (Anderson et al., 2003; Chen et al., 2004; 
Beilhack et al., 2005; Dutt et al., 2007; Zheng et al., 2008). The mechanisms why TEM fail to 
cause GVHD remains unclear. One controversial hypothesis proposes differences in 
migration and priming (Beilhack et al., 2005; Anderson et al., 2008), since TEM do not express 
CD62L and CCR7, and are therefore relatively excluded from lymph nodes (Gunn et al., 
1998). In line with this, when scanning whole SLOs in high resolution we quantified low 
numbers of CD4+ TEM cells homing to T cell areas of PPs and mLNs. Hence, LSFM gave us 
new insights in migration and dispersal of different T cell subtypes after HCT and will prove 
useful to optimize cellular therapies. The ability to detect and automatically count rare events 
in micrometer resolution within large tissue samples, suggests LSFM as an effective tool to 
study single hematopoietic stem cells (Wagers et al., 2002), tumor-draining lymph node 
infiltrating immune cells (Kohrt et al., 2005) or even to identify cancer stem cells (Al-Hajj et 
al., 2003). 
In conclusion, we have shown multicolor LSFM as advantageous for multiple research 
applications in biomedicine and immunology, particularly in inflammatory processes, such as 
GVHD, to track clonal cell distribution throughout the body. Due to the speed and its 
automatable operation, LSFM may advance systematic and comprehensive large-scale 
studies of cell migration and interaction within various tissues, in experimental animal models 
as well as human tissue biopsies. Biomedical research, that translates scientific progress into 
clinical approaches will highly benefit from the application of this high resolution and high 
throughput technology. Therefore, 3D multicolor LSFM holds the promise to complement 
classical histopathological diagnosis.  
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5.2 Relevance of tissue alloantigen expression for the selective 
GVHD organ manifestation 
5.2.1 Alloantigen expression determines organ infiltration of TCR transgenic CD8+ T 
cells after single antigen mismatch allo-HCT 
Alloantigen expression on host epithelium is crucial for the induction of acute GVHD in MHC-
matched, minor histocompatibility antigen–mismatched (miHAg-mismatched) models of HCT 
(Jones et al., 2003). Here we used a TCR transgenic model of GVHD that target a single 
peptide antigen and therefore resembles a MHC-matched single antigen mismatched 
miHAg-mismatched HCT. We investigated the importance of alloantigen expression for the 
selective organ manifestation after HCT into conditioned hosts that either express the peptide 
antigen ovalbumin ubiquitously or selectively in the pancreas, an organ that is normally not 
affected by acute GVHD. At day+6 after HCT we found that TCR transgenic CD8+ T cell 
infiltrated either all organs (βa-Ova) or only the pancreas (RIP-mOva) respectively to the site 
of antigen expression. Hence, in this mouse model of MHC class I dependent antigen 
recognition we could identify an alloantigen dependent organ infiltration of OT-I T cells after 
HCT. 
Although MHC I molecules have a broad tissue expression pattern (Shlomchik, 2007), 
alloreactive T cells mainly affect gut, liver, and skin following MHC-mismatched HCT. In 
contrast miHAgs can differ in their range and distribution of tissue expression. Furthermore in 
a MHC matched, miHAg mismatched HCT a direct target-cell–T-cell contact is required for 
CD8+ T-cell-mediated acute GVHD and therefore the tissue expression pattern of miHAgs 
could reflect which organs are involved in the disease, as demonstrated in our experiments. 
This would imply that certain acute GVHD relevant miHAgs are predominantly or even 
exclusively expressed in the target organs of acute GVHD. However, recently Toubai et al. 
(2012) experimentally demonstrated that an ubiquitously expressed clinically relevant H-Y 
miHAg antigen can cause acute GVHD, by using H-Y specific TCR transgenic CD8+ T cells 
(Matahari). After HCT they assessed acute GVHD by monitoring survival and amongst other 
parameters also analyzed GVHD target organs histopathologically, but did not investigate the 
fate of further peripheral organs that are typically non-target during acute GVHD, such as 
pancreas or kidneys. Nonetheless, when alloantigen expression on host epithelium is 
necessary for the induction of tissue selective acute GVHD, further mechanisms preventing 
tissue infiltration in non-target must exist. Strikingly, we found non-target organ infiltration 
after HCT when the organs expressed the cognate alloantigen. 
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In a MHC-matched, multiple miHAg-mismatched mouse model it was demonstrated that 
CD8+ T cell mediated acute GVHD required direct interactions between TCRs on donor CD8+ 
T cells and MHC I on target tissues (Matte-Martone et al., 2008). In this study, recipient mice 
were chimeras that express MHC I on hematopoietic cells, allowing the activation of 
alloreactive CD8+ T cells, but allo-antigen was not expressed on parenchymal cells as 
chimeric mice were deficient for MHC I (wt  β2M-/- chimeric mice). Importantly, Matte-
Martone et al. (2008) did not detect tissue infiltrating T cells, highlighting the importance of 
parenchymal alloantigen expression for donor CD8+ T cell infiltration. This observation is in 
accordance with our findings, that the parenchymal alloantigen expression determined the 
organ infiltration after allo-HCT. The hampered infiltration might be explained by the inability 
of CD8+ T cells to mediate tissue damage that might either promote an accumulation of 
further donor CD8+ T cells by local retention and survival of T cells after entering target 
tissues, or result in an increased T-cell recruitment from the blood (Matte-Martone et al., 
2008). Although this suggestion might explain the importance of parenchymal antigen 
presentation in T cell infiltration of certain tissues after HCT, it could not clarify the tissue 
selective organ infiltration in acute GVHD. Non-target organs of acute GVHD, that normally 
also express parenchymal antigen, are not affected by T cell infiltration after allogeneic HCT. 
When we transplanted OT-I T cells into established chimeras expressing the antigen 
ovalbumin only by hematopoietic cells we found an organ infiltration, although the 
parenchymal tissue did not express the alloantigen. However, in contrast to the experiments 
by Matte-Martone et al. (2008) in our experiments the recipients were not impaired in 
presenting peptides via MHC I and thus the alloantigen might be released from apoptotic 
hematopoietic cells and cross-presented by parenchymal cells, as discussed later in chapter 
5.2.5.  
In HCT of OVA specific T cells, βa-Ova recipients were chosen to mimic a clinically relevant 
model of ubiquitously cognate antigen expression, a situation that one might anticipate for 
allorecognition if single alloreactive T cells recognize ubiquitously expressed allogeneic MHC 
complexes. However, in contrast to the observed selective GVHD target-tissue manifestation 
of other acute GVHD models, we found, after a massive proliferation phase, ubiquitous organ 
infiltration by antigen specific T cells followed by 50% survival. Also, previous studies 
employing defined alloreactive TCR transgenic T cell clones observed only limited acute 
GVHD manifestation in allo-HCT recipients. HCT of TCR transgenic CD8+ T cells into antigen 
expressing recipients resulted in a short burst of T cell expansion, followed by apoptosis or 
anergy (Rocha et al., 1995; Yu et al., 1999). However, using 2C (Yu et al., 2006) or H-Y 
(Toubai et al., 2012) TCR transgenic CD8+ T cells clinical models of acute GVHD with target 
organ infiltration and mortality could be established. Interestingly, 2C CD8+ TCR transgenic 
cells were more pathogenic in recipients with an intermediate-affinity alloantigen than in 
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those with a high-affinity alloantigen (Yu et al., 2006). However, alloantigen affinity in both, 
βa-Ova and RIP-mOva mice is equal, but only caused in the latter recipients high mortality. 
Nonetheless, there is a discrepancy in the priming of TCR transgenic CD8+ T cells between 
RIP-mOVA and βa-Ova recipients. In RIP-mOVA recipients ovalbumin is mainly restricted to 
pancreatic β cells and TCR transgenic CD8+ T cells are primed via cross-presentation. In 
contrast, all cells of βa-Ova recipients express ovalbumin, including APCs, allowing for direct 
priming of TCR transgenic CD8+ T cells. 
In previous studies OT-I T cells were adoptively transferred into RIP-OVA (Kurts et al., 1996) 
or iFABP-OVA transgenic mice (Vezys et al., 2000) and activation and proliferation was 
observed in lymph nodes draining the ovalbumin expressing tissues. However, in these 
studies tissue destruction was not observed (Kurts et al., 1996; Vezys et al., 2000) and 
transferred OT-I T cells either became anergic (Vezys et al, 2000) or were deleted (Kurts et 
al., 1997b, 1999), except if more than 5 x 106 OT-I T cells were transferred (Kurts et al., 
1997a). Concordantly, 5 x 106 OT-I T cells adoptively transferred into K14-mOVA transgenic 
mice regularly induced GVHD-like inflammatory skin inflammation and tissue damage, 
whereas less cells did not induce significant inflammatory reactions (Shibaki et al., 2004). 
Analysis of RIP-mOVA mice that were adoptively transferred with less than 5 x 106 OT-I T 
cells suggested that the TCR transgenic CD8+ T cells were lost, probably due to deletion, 
after entry in the peripheral tissues (Kurts et al., 1997b). In most mouse models of transgenic 
self-antigen presentation an additional inflammatory signal such as viral infection (Oldstone 
et al., 1991; Vezys et al., 2000) or sublethal irradiation (Azukizawa et al., 2003) was 
generally required to initiate disease. Most mouse models of acute GVHD involve 
myeloablative irradiation for host conditioning and, therefore, to model allo-HCT we also 
used this conditioning regimen before transfer of OT-I T cells into RIP-mOva recipients.  
In contrast to the restriction to gut, liver, and skin in acute GVHD, we found that after HCT 
also other organs had been infiltrated in an antigen dependent manner. However, it must be 
kept in mind that we used transgenic mouse models and therefore results have to be 
interpreted with caution. Monoclonal TCR transgenic CD8+ T cells, such as OT-I T cells, 
possess a relatively high-avidity for antigen (Heath et al., 1993). Furthermore the nature of 
precursor frequency of alloreactivity in this TCR transgenic T cell model amounts to 100% 
and thus differs from polyclonal T cell responses in multiple miHAg-mismatched allo-HCT.  
5.2.2 Effective T cell mediated destruction of alloantigen expressing target tissues 
We had hypothesized that the high numbers of proliferating OT-I T cells may compete for 
resources and survival factors, such as IL2, and therefore failed to cause lethal tissue 
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damage in βa-Ova recipients. However, we found that HCT of lower OT-I cell numbers into 
βa-Ova recipients led to a higher survival rate, which did not support our initial hypothesis.  
In RIP-mOva mice, Kurts et al. (1997a) demonstrated that in the absence of irradiation the 
transfer of high OT-I T cell numbers (> 5 x 106) is sufficient to effectively cause diabetes. We 
found that after irradiation the transfer of as little as 100 OT-I T cells sufficed to effectively 
cause diabetes with 100% mortality. In comparison to RIP-mOva recipients that had received 
high OT-I cell numbers (1 x 105 – 1 x 106), recipients of lower numbers developed diabetes 
later, that was followed by a delayed mortality. Cell number dependent course and outcome 
of an autoimmune disease is observed in many experimental mouse models of acute GVHD 
(Schroeder and DiPersio, 2011) and diabetes (Kurts et al., 1997a). Yet, we could 
demonstrate that the alloantigen recognition of OT-I T cells is highly effective and even very 
few cells were sufficient for localization and destruction of alloantigen expressing cells. 
Hence, also the expression of a single miHAg should be sufficient to cause acute GVHD 
even when the precursor frequency is very low. 
5.2.3 Quantification of organ infiltrating OT-I T cells with FACS 
To directly determine and compare numbers of organ infiltrating OVA specific CD8+ T cells 
after HCT we analyzed tissues of different recipients with FACS at defined time points. In βa-
Ova recipients we detected high OT-I T cell numbers already at day+4 after HCT, 
demonstrating a massive T cell proliferation and accumulation in peripheral tissues. In 
contrast, at day+4 we found in RIP-mOva as well as in B6 recipients very few OT-I T cells in 
almost all peripheral organs. This few early migrating T cells could probe peripheral tissues 
for cognate antigen. At sites of alloantigen recognition probing T cells could engage in their 
effector mechanisms, including direct target cell killing and cytokine production and 
consequently directly or indirectly attract further T cells to this site. Accordingly, from day+4 to 
day+6 we detected a slight increase of OT-I T cells, similar between organs of RIP-mOva and 
B6 recipients, but for the pancreas. In the pancreas of RIP-mOva recipients OT-I T cells 
increased by more than 100 fold, suggesting a specific trafficking or recruitment of donor OT-
I T cells.  
In infections, pathogen-induced tissue inflammation might specifically dictate effector T cell 
migration. Mouse models of acute GVHD rely on total body irradiation for recipient 
conditioning, inducing a systemic inflammation rather than a tissue specific irritation. One 
would hypothesize that without any tissue specific signal the activated antigen specific T cells 
should randomly migrate from SLOs to peripheral organs where they might encounter by 
chance their cognate antigen when entering a tissue. We observed a specific accumulation 
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of donor OT-I T cells in the pancreas of RIP-mOva mice. This phenomenon might be 
explained either by direct T cell guiding mechanisms such as recruitment by selective 
endothelial antigen presentation in the pancreas, or by clues released by early probing T 
cells that had randomly encountered cognate antigen. Yet, remarkably, organ manifestation 
in acute GVHD was restricted to selective tissues that neither in mouse models nor in 
patients involve the pancreas.  
5.2.4 Identification of organ infiltrating OT-I T cells with LSFM 
As we could demonstrate that LSFM is an effective tool for detecting single cells in large 
specimen, we applied this versatile technique to screen large tissue samples of intact 
organs, with the goal of detecting first organ infiltrating OT-I T cells after HCT. To reveal the 
kinetics of T cell migration and organ infiltration following HCT we applied repeated sampling. 
Remarkably, in RIP-mOva recipients we found very low numbers of first islet infiltrating T 
cells on day+4 after HCT followed by a massive T cell migration to the pancreas within the 
following 24h. The kinetic of this T cell migration suggests a targeted recruitment to the tissue 
of alloantigen expression. Importantly, although we found few OT-I T cells in various other 
organs of RIP-mOva recipients between day+3 and day+6 after HCT, such a massive T cell 
migration only occurred to the pancreas. Thus we postulate that the first target antigen 
recognizing OT-I T cells might directly or indirectly contribute to attract further T cells to the 
pancreas.  
In a mouse model of vaginal HSV-2 infection, Nakanishi et al. (2009) found that CD4+ effector 
T cells enter the infected vaginal mucosa prior to CD8+ effector T cells. They demonstrated 
that these early infiltrating CD4+ T cells secrete IFN-γ, presumably upon antigen contact, and 
stimulated the vaginal epithelium to secrete CXCL9 and CXCL10, guiding the CD8+ T cells 
migration into the infected tissues (Nakanishi et al., 2009). The CD4+ T cell migration to the 
infected tissues itself, might already be promoted by the IFN-γ secreting natural killer (NK) 
cells that are involved early after vaginal HSV-2 infection (Nakanishi et al., 2009). 
Nonetheless, in this model of HSV-2 infection, CD4+ T cells appear to serve as the pathfinder 
for an effective CD8+ T cell recruitment. In our study we transferred TCR transgenic OVA 
specific CD8+ T cells only, excluding the involvement of antigen specific donor CD4+ T cells 
that may have facilitated an effective CD8+ T cell recruitment. Vaginal HSV-2 infection causes 
a tissue selective inflammation, promoting tissue specific innate immune processes that in 
turn might facilitate adaptive immune responses. In contrast, in our experiments that mimic 
the clinical scenario of HCT the recipients underwent total body irradiation, causing systemic 
inflammation. It is possible that in this scenario the very early migrating effector T cells 
randomly scan all organs and upon cognate antigen encountering subsequently facilitate an 
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effective recruitment by the bulk of activated effector T cells. Such a hypothetical model 
would be in accordance with our observation that we found few OT-I T cells in various organs 
of RIP-mOva recipients at day+4 after HCT. Only in the ovalbumin-expressing pancreas we 
found a subsequent steep increase of infiltrating antigen specific OT-I T cells. Hence, we 
postulate that first target antigen recognizing OT-I T cells may act as pathfinder that directly 
or indirectly trigger a signal cascade, e.g. via the release of cytokines or chemokines to 
induce further T cell attraction to the pancreas. These signals may include IFN-γ and CCL2 
as we detected high levels of these cytokines at day+6 after HCT of OT-I T cells into 
ovalbumin expressing recipients. 
5.2.5 Antigen expression by either hematopoietic, or by parenchymal cells only 
result in alloreactive T cell organ infiltration 
In the setting of HCT alloantigens are expressed on hematopoietic cells, GVHD target 
epithelium and leukemia cells (Asakura et al., 2010). We transplanted antigen specific OT-I T 
cells into established chimeras expressing the antigen ovalbumin either by hematopoietic 
cells or by parenchymal cells only. Interestingly, we found that OT-I T cells infiltrated all 
organs at day+6 after HCT, irrespective of alloantigen expression by hematopoietic cells or 
parenchymal cells. However, in both cases the alloantigen might be released from apoptotic 
cells, caused by conditioning. Cross-presentation by endothelial cells might allow to 
selectively recruit antigen specific CTLs (Kurts et al., 2010). Furthermore, liver endothelial 
cells have been reported to efficiently present exogenous antigens to CD8+ T cells (Limmer 
et al., 2000). In a mouse model of diabetes Savinov et al. (2003) demonstrated that cross-
presentation of the specific antigen by pancreatic endothelium allows for the homing of 
insulin-specific CD8 T cells to the islet. They suggested that endothelial cells may play a 
prominent role in the trafficking of activated T cells, at least for secreted proteins as insulin 
(Savinov et al., 2003). That non-secreted antigens can be cross-presented by endothelial 
cells was also suggested by studies of tissue transplantation models (Kreisel et al., 2002; 
Valujskikh et al., 2002). In light of peptide cross-presentation, endothelial cells can participate 
in the effector phase of T cell-mediated inflammatory responses such as autoimmunity, anti-
tumor immunity, and transplant rejection (Bagai et al., 2005) without the necessity of organ 
specific alloantigen expression by parenchymal cells.  
Another possible mechanism allowing an antigen specific T cell regulation in absence of 
parenchymal alloantigen expression would be cross-presentation of tissue residential DCs. 
CD103+ DCs have been identified to uptake and cross-present tissue antigens after migrating 
into draining lymph nodes (Bedoui et al., 2009). If these DCs can cross-present antigens also 
in peripheral tissues remains unclear and, thus, the ability of DCs in regulating effector CTLs 
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in an antigen-specific manner is unknown (Kurts et al., 2010). Recently, mucosal resident 
CX3CR1+ DCs have been identified to effectively cross-present circulatory or luminal 
antigens and control CD8+ T cell activation (Chang et al., 2013). Nonetheless, DC cross-
presentation cannot elicit epithelial damage that is triggered during acute GVHD, because 
CD8+ T cells require a direct contact to a target-cell to promote killing (Trapani and Smyth, 
2002). However, this contact may induce danger signals or stimulate the T cell for cytokine 
release, followed by further T cell attraction. 
5.2.6 OT-I T cell proliferation ability and IFN-γ production in vitro 
We found high levels of IFN-γ in the serum of ovalbumin expressing recipients (βa-Ova, βa- 
Ova-chimeras and RIP-mOva) of OT-I T cells at day+6 after HCT, indicating an involvement 
of this cytokine in antigen specific OT-I T cell mediated pathology. In vitro activated OT-I T 
cells responded with the production of IFN-γ upon antigen re-encounter. We postulate that 
IFN-γ might be relevant in the alloantigen dependent organ infiltration of antigen specific 
CD8+ T cell infiltration after HCT. 
IFN-γ is a key cytokine in innate and adaptive immune responses by having multiple 
functions on macrophages, NK cells, and T cells (Hu and Ivashkiv, 2009). In acute GVHD 
IFN-γ has the ability to either promote or attenuate the development of disease (Welniak et 
al., 2000; Asavaroengchai et al., 2007; Lu and Waller, 2009; Wang et al., 2009). IFN-γ is 
considered to induce the production of chemokines in target organs during the initial phase of 
GVHD (Schroeder and DiPersio, 2011). Especially the timing of IFN-γ production might 
influence the development and severity of acute GVHD, as immediately after HCT IFN-γ is 
described to mediate immunosuppressive effects but during the GVHD effector phase can 
also amplify GVHD pathology due to its pro-inflammatory properties (Lu and Waller, 2009; 
Blazar et al., 2012). During the pathogenesis of acute GVHD IFN-γ further induces 
chemokines as well as inflammatory responses, enhancing the migration of effector T cells to 
the sites of inflammation (Mapara et al., 2006). Similarly, IFN-γ release is also required for 
inducing further chemokine-production to promote CD8+ T cell entry in the herpes virus 
infected vaginal mucosa (Nakanishi et al., 2009). In a mouse model of diabetes IFN-γ, 
among others, plays an important role in the control of the homing of activated diabetogenic 
T cells to the islets (Savinov et al., 2001). 
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5.2.7 Antigen recognition of alloreactive TCR transgenic CD4+ T cells - proliferation 
and migration of OT-II cells 
When we transplanted TCR transgenic CD4+ T cells (OT II cells) into conditioned βa-Ova 
recipients we observed similarly to OT-I T cell HCT, an effective proliferation and an overall 
organ infiltration at day+6 after HCT, suggesting also an antigen dependent T cell 
distribution.  
MHC II presented peptides derive from extracellular antigens or cytosolic proteins that are 
degraded through autophagy (Crotzer and Blum, 2010; Neefjes et al., 2011). MHC-II 
expression and therefore also antigen presentation is restricted to APCs, such as DCs, B 
cells or macrophages. Also epithelial cells within the gastrointestinal tract have been reported 
to present antigens via MHC II molecules during inflammation (Beers et al., 2005). Recently, 
it could be shown that non-hematopoietic antigen-presenting cells of HCT recipients alone 
are sufficient to induce a CD4+ T cell mediated lethal acute GVHD (Koyama et al., 2011). If 
the migration of OT-II cells depends on the access to alloantigens, both, the site of antigen 
expression and the presentation by APCs could dictate the tissue tropism. Hence, in this 
case the tissue specific distribution of APCs as well as tissue dependent efficiency of antigen 
presentation might influence CD4+ T cell migration. 
In contrast to OVA-specific CD8+ T cells that have to be cross-primed when transferred to 
RIP-mOva recipients, OT-II cells rely on the presentation of peptides in the context of MHC-II 
via professional APCs for activation. After HCT into RIP-mOva recipients OT-II cells did not 
efficiently proliferate and therefore we could not detect migrating antigen specific T cells to 
peripheral tissues, such as the pancreas at day+6. Accordingly, in adoptive transfer 
experiments of OT-II cells into RIP-mOva recipients, Kurts et al. (1997a) found that even high 
numbers of 10 x 106 OVA-specific CD4 T cells failed to induce diabetes. Nevertheless, they 
demonstrated that the coinjection of OVA-specific CD4 helper T cells together with small 
numbers of OVA-specific CD8 T cells increased the incidence of diabetes. This enhancing 
effect of OT-II cells was neither explained by an increased proliferation of OT-I T cells nor by 
an effector function to the pancreatic islet cells, but by an impaired survival of CD8+ T cells 
(Kurts et al., 1997a). Whether CD4+ T cell help was provided in the draining LNs or at the site 
of antigen-expression, was not investigated in this study. 
In conclusion, here we demonstrated the importance of alloantigen expression for the organ 
infiltration of CD8+ T cells after HCT. We found that, depending on the tissue antigen 
expression, also GVHD non-target organs can be infiltrated by alloreactive T cells. At an 
early time point after HCT we found few donor cells distributing in all organs followed by a 
specific recruitment to the alloantigen expressing tissue. This finding might highlight the 
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importance of alloantigen dependent signaling for the further recruitment and accumulation of 
additional CD8+ effector T cells.  
We hypothesize that the selective organ manifestation during GVHD is initiated by first T 
cells that recognize their cognate antigen in peripheral tissues, produce cytokines and thus 
further recruit additional donor T cells. We conjecture that the activation of alloreactive T cells 
in mucosal associated SLOs as well as peripheral antigen presentation may favor the initial 
donor T cell infiltration of the gastrointestinal tract after allo-HCT. However, peripheral 
alloantigen expression directs the organ specific T cell infiltration and the absence of cognate 
antigen from the typical GVHD target tissues can result in an altered organ manifestation as 
demonstrated by our experiments.  
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